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ABSTRACT 
 
TOPOGRAPHICAL DIFFERENCES IN STRESS VULNERABILITY IN EXPERIMENTAL 
PARKINSON’S DISEASE 
 
 
 
By 
Jessica M. Posimo 
December 2015 
 
Dissertation supervised by Dr. Rehana K. Leak  
 Parkinson’s disease is characterized by the progressive spread of protein misfolding 
stress, or proteotoxicity, across the brain. During this protracted process, the allocortex of the 
temporal lobe develops protein inclusions before the neocortex in the frontal and parietal lobes. 
In the present study we tested the hypothesis that the staged appearance of proteotoxicity in 
allocortex followed by neocortex is the result of intrinsic vulnerability differences. We 
microdissected the neocortex and multiple subregions of the allocortex from rat brains and plated 
the primary neo- and allocortical neurons for parallel in vitro studies. Cells were then exposed to 
a number of Parkinson’s disease-mimicking toxins and cellular viability was measured by three 
independent and unbiased assays that we have validated as linear and highly sensitive. As 
expected, neocortex was more resistant to loss of proteasomal degradation of proteins than three 
allocortical subregions: entorhinal cortex, piriform cortex, and hippocampus. Neocortex was also 
 v 
more resistant to α-synucleinopathy than hippocampal allocortex. Entorhinal allocortex exhibited 
lower protein degradative activity than neocortex and greater stress-induced increases in 
misfolded proteins. Entorhinal allocortex also expressed higher stress-sensitive changes in heat 
shock proteins (Hsps) such as Hsp70 and Hsc70, suggesting that allocortex needs to rely more on 
chaperone defenses. In support of this hypothesis, simultaneous loss of Hsp70/Hsc70 and 
proteasome activity was far more toxic in allocortex than neocortex, whereas facilitation of 
Hsp70/Hsc70 activity was protective only in neocortex. Neocortex exhibited higher levels of the 
antioxidants glutathione and ceruloplasmin, and loss of glutathione synthesis rendered neocortex 
as vulnerable to proteotoxicity as allocortex. Consistent with these observations, allocortex was 
protected against proteotoxicity by facilitating glutathione synthesis with N-acetyl cysteine. 
Finally, as aging is a natural model of protein misfolding stress, the levels of select heat shock 
proteins, proteasome subunits, and glutathione were examined in neocortex and allocortex in 
vivo as a function of age. Our findings suggest that the cerebral cortex is more heterogenous than 
previous in vitro studies of this brain region have acknowledged and that the staged appearance 
of protein inclusions in Parkinson’s disease is at least partly determined by topographic 
differences in intrinsic vulnerability to protein misfolding stress. 
 
 
 
 
 
 
 
 vi 
DEDICATION 
 
 This dissertation is dedicated to my parents, Andrea and Joseph Posimo, who have 
provided endless love, support, and encouragement.  
 
 
 
 
 vii 
ACKNOWLEDGEMENT 
 
 I thank my advisor, Dr. Rehana Leak, for encouraging me to pursue my Ph.D. and for 
continuously supporting me throughout my time here at Duquesne University. I would also like 
to thank my committee members, Dr. Jane Cavanaugh, Dr. David Johnson, Dr. Patrick Card, Dr. 
Surratt, and Dr. O’Donnell for their guidance and advice.   
 I thank Dr. Peter Wipf and Dr. Jeffrey Brodsky from the University of Pittsburgh for their 
generosity in providing the Hsp70 modulators for my studies. I would like to thank Dr. Virginia 
Lee and Dr. Kelvin Luk from the University of Pennsylvania for generating the synuclein fibrils 
used in my project. I would also like to acknowledge the assistance of Denise Butler-Buccilli and 
Christine Close in maintaining the animal colonies.  
 I thank all of the graduate students, faculty, and administrative staff in the Graduate 
School of Pharmaceutical Sciences. I would especially like to thank my fellow graduate student, 
Amanda Gleixner, for always providing scientific and personal support, encouragement, and 
friendship.   
 Finally, I thank my family and friends, especially my fiancée, Michael Blenk, whose love 
and support made all of this possible. 
 
 
 
 
 viii 
TABLE OF CONTENTS 
Page 
Abstract ........................................................................................................................... iv-v 
Dedication .......................................................................................................................... vi 
Acknowledgement ............................................................................................................ vii 
List of Figures ................................................................................................................. x-xi 
Introduction ..........................................................................................................................1 
    The Impact of Parkinson's Disease ..................................................................................1 
    Patterns of Neurodegeneration  ........................................................................................2 
        Parkinson’s Disease Staging ........................................................................................2 
        Alzheimer’s Disease Staging .......................................................................................5 
    The Spreading of Lewy Bodies in Parkinson’s Disease ..................................................6 
    Selective Vulnerability in Parkinson’s Disease ...............................................................9 
    Protein Degradation Pathways   .....................................................................................11 
    Neurodegenerative Mechanisms in Parkinson’s disease ...............................................14 
        Accumulation of Misfolded Proteins .........................................................................14   
        Oxidative Stress .........................................................................................................17 
    Protective Molecules Implicated in Protection Against Parkinson’s Disease ...............18 
        Glutathione .................................................................................................................18 
        Ceruloplasmin ............................................................................................................19 
    Aging and Parkinson’s Disease  ....................................................................................21 
Materials and Methods .......................................................................................................24 
Chapter 1 ............................................................................................................................33 
 ix 
    Rationale ........................................................................................................................33 
    Specific Aim 1a ..............................................................................................................34 
         Results .......................................................................................................................34 
        Discussion ..................................................................................................................38 
    Specific Aim 1b .............................................................................................................43 
        Results ........................................................................................................................43 
        Discussion ..................................................................................................................55 
    Specific Aim 1c ..............................................................................................................60 
        Results ........................................................................................................................60 
        Discussion ..................................................................................................................71 
Chapter 2 ............................................................................................................................74 
    Specific Aim 2 ...............................................................................................................74 
        Rationale ....................................................................................................................74 
        Results ........................................................................................................................74 
        Discussion ..................................................................................................................89 
Chapter 3 ............................................................................................................................93 
    Specific Aim 3 ...............................................................................................................93 
        Rationale ....................................................................................................................93 
        Results ........................................................................................................................93 
        Discussion ..................................................................................................................98 
Conclusions ......................................................................................................................101 
References ........................................................................................................................106 
Appendix ..........................................................................................................................127 
 x 
LIST OF FIGURES 
Page 
Figure 1. Caudo-rostral progression of Lewy bodies in the brain in Parkinson’s disease ...5 
Figure 2. Protein degradation pathways in the cell  ...........................................................14 
Figure 3. Characterization of in vitro model ......................................................................35 
Figure 4. Linearity and sensitivity of viability assays in primary postnatal neurons  .......37 
Figure 5. Intra- and inter-experimental variability in viability assays  ..............................38 
Figure 6. Differential vulnerability of neo- and allocortex to toxins  ................................44 
Figure 7. Involvement of autophagic defenses and ubiquitin-proteasome system  ...........47 
Figure 8. Protein changes in neo- and allocortex in response to proteasome inhibition  ..51 
Figure 9. Role of glutathione in protection of neo- and allocortex against proteasome inhibition 
............................................................................................................................................54 
Figure 10. α-synuclein fibrils elicit the formation of neuronal inclusions  ........................61 
Figure 11. α-synuclein inclusion formations are insoluble in detergent  ...........................62 
Figure 12. α-synuclein fibrils elicit Thioflavin S+ amyloid formations  ............................64 
Figure 13. Impact of α-synuclein fibril treatment in neo- and allocortical neurons  .........66 
Figure 14. Effect of α-synuclein fibrils on hippocampal MAP2 levels  ............................68 
Figure 15. Impact of α-synuclein fibril treatment on neuronal and nuclear markers  .......70 
Figure 16. Primary postnatal cultures of neo- and allocortex  ...........................................75 
Figure 17. Regional differences in vulnerability to cellular stress  ...................................77 
Figure 18. Heat shock protein and co-chaperone expression in neo- and allocortical cultures 
............................................................................................................................................80 
 xi 
Figure 19. Allocortical neurons rely more on Hsp70/Hsc70 than neocortical neurons under 
proteotoxic conditions  .......................................................................................................83 
Figure 20. Allocortical neurons rely on HO1 more than neocortical neurons under proteotoxic 
conditions  ..........................................................................................................................84 
Figure 21. Neo- and allocortical astrocytes do not differ in their reliance on Hsp70/Hsc70 
defenses  .............................................................................................................................86 
Figure 22. Paraquat toxicity in neo- and allocortical neurons is not exacerbated by Hsp70/Hsc70 
inhibition  ...........................................................................................................................88 
Figure 23. Impact of natural aging on neocortex and allocortex in vivo ...........................95 
Figure 24. Heat shock proteins and co-chaperones in neo- and allocortex as a function of age in 
vivo .....................................................................................................................................97 
 
 
 
 
 
 
 1 
Introduction  
The Impact of Parkinson’s Disease 
 Parkinson’s disease is the second most common neurodegenerative disorder after 
Alzheimer’s disease. It has a mean age of onset of approximately 60 years and affects about 1 
million people in the United States and 4 million people worldwide (Shehadeh et al., 2010). Age 
is the major risk factor for Parkinson’s disease as its prevalence rises from 1% in those over 60 
years of age to 4% of the population in those over 80 (D. T. Dexter & Jenner, 2013).  
Parkinson’s disease is more prevalent in men than in women with reports of ratios ranging from 
1.1:1 to 3:1 (Schrag, Ben-Shlomo, & Quinn, 2000). The socioeconomic impact of the disease can 
be high with a cost per patient per year of approximately $10,000 in the United States. Indeed, 
the total economic burden of Parkinson’s disease has been estimated at $23 billion (Huse et al., 
2005; Whetten-Goldstein, Sloan, Kulas, Cutson, & Schenkman, 1997). Expenses associated with 
inpatient care and nursing homes account for the majority of this cost rather than medication-
related costs (Huse et al., 2005). 
 The clinical diagnosis of Parkinson’s disease is based on the identification of impaired 
motor function with symptoms of bradykinesia, rigidity, resting tremor, and/or postural 
instability. These motor symptoms reflect the loss of dopaminergic neurons in the substantia 
nigra pars compacta (SNpc) and subsequent decrease in dopamine levels in the striatum. 
Identification of the hallmark motor symptoms and a positive response to dopaminergic 
medications help to solidify the clinical diagnosis of Parkinson’s disease. Recently, Parkinson’s 
disease has been hypothesized to be an even more complex, systemic illness than previously 
thought, involving both motor and non-motor symptoms such as depression, sleep disturbance, 
sensory abnormalities, autonomic dysfunction, and cognitive decline (Langston, 2006). Non-
 2 
motor symptoms of the disorder usually antedate motor symptoms by many years (Koller, 1992). 
Autonomic dysfunction and an impairment in or loss of olfaction are frequently reported years 
before motor symptoms are manifest (Hawkes, Shephard, & Daniel, 1997). At the very end 
stages of Parkinson’s disease, progressive cognitive decline begins to devastate patients and their 
families (Dubois & Pillon, 1997). Non-motor symptoms are thought to affect all patients but are 
poorly diagnosed despite being a major determinant of disease outcome, decreased function and 
quality of life, and forcing entry into long-term care (Chaudhuri, Healy, Schapira, & Excellence, 
2006; D. T. Dexter & Jenner, 2013; Schenkman, Wei Zhu, Cutson, & Whetten-Goldstein, 2001).  
Furthermore, the etiology of non-motor symptoms remains poorly researched compared to the 
motor deficits (D. T. Dexter & Jenner, 2013). Nevertheless, recent breakthroughs have 
established that Parkinson’s disease affects both the peripheral and central nervous systems, 
progresses systematically over time, affects movement in mid-to-late stages, and impairs 
cognition in end stages (Jellinger, 2011). 
Patterns of Neurodegeneration 
Parkinson’s Disease Staging 
 In 2003, the German neuroanatomist Heiko Braak and his colleagues proposed that 
Parkinson’s disease could be categorized into six distinct stages based on histopathology, now 
known as Braak stages 1-6 (H. Braak, Del Tredici, Rüb, et al., 2003). Braak staging was based 
on the neuroanatomical distribution of proteinaceous inclusions in postmortem idiopathic 
Parkinson’s diseased brains. The signature histopathological lesions of the disorder include 
eosinophilic inclusions within the cytoplasm or in dendritic and axonal processes. These 
inclusions are termed Lewy bodies and Lewy neurites, after Fritz Heinrich Lewy, who first 
reported these pathological markers in 1912 (Goedert, Spillantini, Del Tredici, & Braak, 2013). 
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These hallmark inclusion bodies can develop as spindle or thread-like Lewy neurites in cellular 
processes or globular Lewy bodies in neuronal perikarya (Pollanen, Dickson, & Bergeron, 1993). 
The major component of these lesions is the normally presynaptic protein α-synuclein, which 
misfolds and aggregates in all or nearly all Parkinson’s disease cases (Baba et al., 1998; Duda, 
Lee, & Trojanowski, 2000).  Histological studies of the pathology in familial forms of 
Parkinson’s disease are somewhat limited in scope, but it nevertheless recognized that all or 
nearly all patients with Parkinson’s disease exhibit loss of nigral dopamine neurons and Lewy 
pathology in this brain region (Farrer et al., 2001; Mori et al., 1998). Thus, Lewy bodies and 
Lewy neurites are present in both sporadic and familiar forms of Parkinson’s disease, consistent 
with their centrality to the disease process (Poulopoulos, Levy, & Alcalay, 2012).  
 According to the Braak staging theory, new regions are progressively affected by Lewy 
pathology with each successive stage, while the pathology increases in severity in previously 
affected brain regions (Fig. 1)(H. Braak, Del Tredici, Rüb, et al., 2003; Luk & Lee, 2014). In 
stage 1, the medulla oblongata develops lesions in the dorsal IX/X motor nucleus and/or the 
intermediate reticular zone as well as anterior olfactory structures such as the anterior olfactory 
nucleus and olfactory bulb mitral cells (Daniel & Hawkes, 1992).  This pathology is exacerbated 
in stage 2 and the pontine tegmentum becomes gradually involved, with Lewy bodies appearing 
in the caudal raphe nuclei, gigantocellular reticular nucleus, and coeruleus-subcoeruleus 
complex. In stage 3, lesions finally develop in the midbrain, particularly the melanin-laden 
neurons of the SNpc while the severity of the previously developing lesions increases in 
magnitude. Additionally, the second sector of the Ammon’s horn in the large hippocampal 
formation also begins to develop long Lewy neurites at this middle stage (H. Braak, Del Tredici, 
Rüb, et al., 2003). 
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The cerebral cortex is responsible for higher-order executive function, learning, and 
memory, and Lewy bodies and Lewy neurites in this structure are therefore correlated with 
symptoms of dementia and cognitive decline (Harding & Halliday, 2001; Hurtig et al., 2000; 
Mattila, Rinne, Helenius, Dickson, & Röyttä, 2000). Cortical involvement begins at Braak stage 
4 and is confined to the temporal mesocortex, specifically the transentorhinal region, and the 
limbic allocortex. There is continued marked devastation in the melano-neurons of the SNpc as 
well as the anterior olfactory nucleus at this stage. Specifically, Lewy-bearing inclusions increase 
in number and there is significant loss of neurons in the posterior region of the SNpc. Lesions 
also begin affecting the central nuclei of the amygdala and specific subnuclei of the thalamus at 
mid to end stages. In stage 5, lesions progress into high order sensory association areas of the 
neocortex and prefrontal cortex while all previously affected subcortical and mesocortical 
structures exhibit even more severe pathology. At the final stage 6, nearly the entire neocortex is 
involved, including first order sensory association areas and premotor areas with occasional mild 
changes in primary sensory areas and the primary motor field (H. Braak, Del Tredici, Rüb, et al., 
2003). Thus, the primary sensorimotor neocortex is the last cortical subregion to be affected by 
the disease process whereas the entorhinal allocortex is the first. 
 
 5 
 
Figure 1. Caudo-rostral progression of Lewy bodies in the brain in Parkinson’s disease. Reprinted from “Milestones 
in Parkinson's disease—Clinical and pathologic features,” by G. Halliday, A. Lees, and M. Stern, 2011, Movement 
Disorders, 26, p. 1015-1021. Copyright 2011 by John Wiley and Sons.  Reprinted with permission. 
 
Alzheimer’s Disease Staging 
 Similar to Parkinson’s disease, Alzheimer’s disease is also thought to spread across 
multiple brain regions, although postmortem studies of Alzheimer’s patients have mostly focused 
upon neurodegeneration in the cerebral cortex. In both disorders, the temporal mesocortex and 
allocortex seem to be the nucleation site for the spread of protein aggregations in the 
telencephalon, while the neocortex is affected last (H. Braak, Rüb, Schultz, & Del Tredici, 
2006). However, in Alzheimer’s disease, the major component of the intraneuronal 
aggregations–known as neurofibrillary tangles–is the microtubule-associated protein tau (E. 
Braak, Braak, & Mandelkow, 1994).  
Braak staged Alzheimer’s disease based on the regional distribution of neurofibrillary 
tangles. In stages I and II, meso- and allocortical regions such as the transentorhinal and 
entorhinal cortices exhibit tau pathology, followed by involvement of the hippocampus. In stages 
III-IV, there is exacerbation of pathology in the entorhinal cortex and commencement of 
pathology in higher order neocortical areas of the temporal lobe. Finally, in end stages V-VI, 
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neocortical involvement becomes more severe and encroaches on primary sensorimotor areas of 
the frontal and parietal neocortex (H. Braak, Rüb, et al., 2006). This staging scheme has been 
correlated with intellectual status (Bancher, Braak, Fischer, & Jellinger, 1993). In addition, the 
degeneration of the entorhinal cortex in Alzheimer’s disease has been correlated to a severe 
decline in both memory and executive function (Albert, 1996; Gómez-Isla et al., 1997; Kordower 
et al., 2001).  It is worth noting that amyloid formation begins in the neocortex in Alzheimer’s 
disease, but that total plaque numbers do not correlate to disease severity or loss of neurons 
(Gómez-Isla et al., 1997; Ingelsson et al., 2004; Josephs et al., 2008; Thal, Rüb, Orantes, & 
Braak, 2002). In addition, atrophy in the cerebral cortex follows the progression of tau 
pathology, not of amyloid formations (Arriagada, Growdon, Hedley-Whyte, & Hyman, 1992; 
Josephs et al., 2008).  
The Spreading of Lewy Bodies in Parkinson’s Disease 
 As mentioned previously, the main component of Lewy bodies is the protein α-synuclein, 
a 14 kDa protein consisting of 140 amino acids that interacts with highly curved phospholipid 
membranes, such as presynaptic vesicles. α-synuclein appears to play a dynamic role in vesicle 
trafficking during neurotransmitter release, though its exact function is still a matter of some 
debate (Recasens & Dehay, 2014). There are six known missense mutations in the gene encoding 
α-synuclein that have been found to mandate the onset of autosomal-dominant forms of 
Parkinson’s disease (Appel-Cresswell et al., 2013; Athanassiadou et al., 1999; Krüger et al., 
1998; Lesage et al., 2013; Polymeropoulos et al., 1997; Zarranz et al., 2004). Additionally, 
overexpression of α-synuclein due to gene duplication or triplication has been identified as a 
cause of some forms of familial Parkinson’s disease (Goedert et al., 2013). Furthermore, the 
most important genetic risk factor for idiopathic Parkinson’s disease is sequence variation in the 
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regulatory region of the gene encoding for α-synuclein, as identified by a genome-wide 
association study (Krüger et al., 1999). These findings highlight the importance of α-synuclein 
for Lewy body disorders.  
 α-synuclein is a natively unfolded protein, having no defined structure in aqueous 
solution. However, under pathological conditions, such as oxidative stress, gene mutations, or 
following post-translational modifications (such as phosphorylation, ubiquitination, or 
truncation), it can adopt an oligomeric or fibrillar conformation, which can elicit aggregation and 
Lewy body formation (Recasens & Dehay, 2014). Growing bodies of evidence indicate that the 
soluble pathogenic form of α-synuclein may self-propagate and spread progressively between 
interconnected brain regions via cell-to-cell transmission, similar to the prion hypothesis in 
Creutzfeld-Jacob disease. This idea of transmissibility is supported by Braak’s six-stage scheme 
of Parkinson’s disease progression, which maps the spread of Lewy body pathology in a caudo-
rostral topographical manner (H. Braak, Del Tredici, Rüb, et al., 2003). In two independent 
studies, embryonic mesencephalic neurons were grafted into the striatum of Parkinson’s patients. 
Remarkably, after a number of years, patients developed α-synuclein-positive Lewy bodies in the 
grafted neurons, indicating a host-to-graft transmission of synucleinopathy in the human brain 
(Kordower, Chu, Hauser, Freeman, & Olanow, 2008; Li et al., 2008). A potential mechanism for 
this transmission could be the release of fibrillized or oligomeric α-synuclein by exocytosis or 
necrosis into the extracellular milieu. Neighboring neurons might take up α-synuclein through 
endocytotic pathways. Once inside the cell, misfolded a-synuclein might act as a template, 
promoting the misfolding of neighboring synuclein molecules, ultimately leading to further 
Lewy body formation (Brundin, Li, Holton, Lindvall, & Revesz, 2008).  
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 Recent in vitro studies have shown that synthetic recombinant preformed α-synuclein 
fibrils can act as a seed to induce endogenous soluble α-synuclein to misfold into insoluble 
hyper-phosphorylated and ubiquitinated pathologic species (Luk et al., 2009; Volpicelli-Daley et 
al., 2011b). Disruption of synaptic function, neuronal excitability and connectivity, and eventual 
neuronal death follows α-synuclein aggregation formation in the recipient cells. In vivo studies 
have also shown α-synuclein can spread via cell-to-cell transmission (Luk, Kehm, Zhang, et al., 
2012). Hansen and colleagues demonstrated host-to-graft transfer of α-synuclein, as grafted fetal 
post-mitotic dopaminergic neurons exhibited human α-synuclein immunoreactivity 6 months 
after transplantation into the striatum of mice overexpressing human α-synuclein (Hansen et al., 
2011). In addition, intracerebral injections of synthetic recombinant preformed α-synuclein 
fibrils or brain homogenates from aged α-synuclein transgenic mice into the neocortex and 
striatum of young asymptomatic transgenic mice have been shown to induce widespread 
Parkinson’s disease-like pathology and reduce the lifespan of the mice (Luk, Kehm, Zhang, et 
al., 2012). These findings were recently reproduced by Mougenot and colleagues, who showed 
that injections of brain homogenates from symptomatic α-synuclein transgenic mice into the 
brains of younger, healthy transgenic mice subsequently reduced their lifespan and accelerated 
the clinical signs of paralysis characteristic of this mouse model (Mougenot et al., 2012). Finally, 
injection of α-synuclein fibrils into wild type mice has also been shown to induce pathological 
spreading of α-synuclein (Luk & Lee, 2014).  
The studies outlined above all support Braak’s hypothesis that the pattern of spread of 
Lewy pathology from allocortex to neocortex may be explained by an insult traveling across the 
cortex in a transneuronal fashion. In addition to transneuronal spread across interconnected brain 
regions, we believe that selective regional vulnerabilities may also play a role in determining 
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which brain regions are first seized into developing protein misfolding stress and exhibiting 
Lewy formations.  
Selective Vulnerability in Parkinson’s Disease 
As mentioned above, Parkinson’s disease is characterized by the severe loss of 
nigrostriatal dopamine neurons and the formation of α-synuclein-laden protein aggregations 
termed Lewy bodies in many brain regions. By end stages of the disease, 80-95% of neurons in 
the ventral tier (nigrosome 1) of the SNpc degenerate, whereas more dorsally and medially 
situated dopamine neurons are mostly spared from cell death (Damier, Hirsch, Agid, & Graybiel, 
1999). The reason for this differential susceptibility is unknown.  Cells of the dorsal tier are 
innervated by dorsal striatal afferents from the caudate nucleus whereas ventral tier cells receive 
projections from the caudate nucleus and putamen (Haber, Fudge, & McFarland, 2000). Thus, it 
is possible that susceptibility is influenced by variations in neuronal afferent and efferent 
projections. Differential receptor expression in these areas may also play a role in determining 
selective vulnerability to neurodegeneration. The dopamine type 2 (D2) receptor is one of the 
most abundant receptors in the SNpc (Hurd, Suzuki, & Sedvall, 2001). Binding of this receptor 
results in an efflux of potassium and the subsequent inhibition of neuronal activity and reduced 
dopamine release (Luján, Maylie, & Adelman, 2009). In the more vulnerable ventral tier of the 
SNpc, higher levels of D2 receptor mRNA have been reported than in the dorsal tier in 
postmortem studies of the human brain (Hurd, Pristupa, Herman, Niznik, & Kleinman, 1994). 
Furthermore, SNpc neurons utilize L-type voltage-gated Ca2+ channels to drive the firing of 
action potentials (Nedergaard, Flatman, & Engberg, 1993). This lies in contrast to ventral 
tegmental area neurons, which use Na+ based ion channels (Puopolo, Raviola, & Bean, 2007). 
Thus, SNpc neurons exhibit higher levels of intracellular Ca2+ than ventral tegmental area 
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neurons. In addition, there is a scarcity of calcium binding proteins in the SNpc, with calbindin 
being absent and paravalbumin and calretinin only sparsely expressed within subregions of the 
SNpc (McRitchie, Hardman, & Halliday, 1996). These observations are important because a high 
Ca2+ microenvironment is thought to increase mitochondrial metabolic activity and subsequent 
production of reactive oxygen species, thereby increasing stress vulnerability.  
 Many decades ago, Parkinson’s disease was shown to involve a dramatic increase in iron 
in the SNpc (Double et al., 2008). Increased iron levels are known to catalyze the production of 
reactive oxygen species through Fenton chemistry (Rhodes & Ritz, 2008) and may promote α-
synuclein fibrillization, which is strongly linked to Lewy body formation (Uversky, Li, & Fink, 
2001). The major cellular iron transport mechanism is dependent upon the protein transferrin, 
including melanotransferrin and lactotransferrin, which shuttle iron in and out of cells. 
Immunoreactivity for lactotransferrin is higher in the ventral tier of the SNpc in Parkinson’s 
disease (Faucheux et al., 1995). These findings suggest that the ventral tier of the SNpc has a 
greater capacity to engage in iron flux.  Therefore, regional differences in iron transport 
mechanisms may also play a role in the selective vulnerability of SNpc neurons in Parkinson’s 
disease. 
 Finally, antioxidant and neurotransmitter systems may also contribute to the enhanced 
susceptibility of SNpc neurons to neurodegeneration in Parkinson’s disease. In one microarray 
study, a number of glutathione-related genes were shown to be downregulated in the vulnerable 
ventrolateral SNpc in the human brain (Duke, Moran, Pearce, & Graeber, 2007). Studies in 
human and non-human primates further show that levels of the dopamine transporter are higher 
in neurons of the more vulnerable ventral tier than other SNpc subregions (González-Hernández, 
Barroso-Chinea, De La Cruz Muros, Del Mar Pérez-Delgado, & Rodríguez, 2004). Thus, this 
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region may experience higher levels of oxidative stress due to enhanced dopamine reuptake from 
the synapse and subsequent metabolism.   
 The studies described above sought to examine the selective vulnerability of the SNpc in 
Parkinson’s disease. In contrast, our studies are the first to examine topographical vulnerability 
differences between the least resistant cortical region, the entorhinal cortex, and the most 
resistant cortical region, the primary sensorimotor neocortex. Specifically, we investigated 
differences in endogenous defensive proteins as well as protein degradation pathways in these 
cortical subregions.  
Protein Degradation Pathways 
Molecular chaperones regulate the folding, disaggregation, degradation, and trafficking 
of protein substrates within the cell  (Fig. 2) (Kim, Hipp, Bracher, Hayer-Hartl, & Hartl, 2013). 
They are highly conserved and can be broadly grouped into Hsp70, Hsp90, DNAJ/Hsp40, 
chaperonin/Hsp60, and small heat shock protein families (Haslbeck, Franzmann, Weinfurtner, & 
Buchner, 2005; Kim et al., 2013). Members of the Hsp70 and Hsp90 families are the best studied 
and require ATP hydrolysis for chaperone activity (Kim et al., 2013). In contrast, small heat 
shock proteins, such as Hsp27, influence protein folding in an ATP-independent manner by 
forming oligomeric cages that trap misfolded proteins, preventing them from aggregating, and 
creating a reservoir of substrates for Hsp70 (Haslbeck et al., 2005). The chaperonin Hsp60 is 
formed by two large hexameric ring complexes that encapsulate the substrate protein into a 
central cavity so that folding can be unimpaired by aggregation (Kim et al., 2013).   
Client specificity and the functionality of Hsp70 and Hsp90 are strongly influenced by 
interactions with a range of co-chaperones (Taipale et al., 2014). Hsp90 associates with a number 
of co-chaperones while Hsp70 is principally regulated by Hsp40, which stimulates its ATPase 
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activity (Kampinga & Craig, 2010; Taipale, Jarosz, & Lindquist, 2010). In addition, the co-
chaperones Hsc70/Hsp70 organizing protein (Hop) and Hsc70-interacting protein (Hip) can bind 
together the Hsp70 and Hsp90 machinery and stabilize the ADP-bound state of the chaperones 
that have a high affinity for substrate proteins (Hohfeld, Minami, & Hartl, 1995; Taipale et al., 
2010). On the other hand, recruitment of the co-chaperones C-terminus of Hsc70-interacting 
protein (CHIP) and Bcl2-associated athanogene 1 (BAG1) redirects Hsp70 and Hsp90 client 
proteins to the proteasome for degradation (Connell et al., 2001; Demand, Alberti, Patterson, & 
Hohfeld, 2001). Thus, chaperones can act alone or in concert with different co-chaperones to 
refold or eliminate misfolded proteins through the proteasome.   
The 26S proteasome consists of a 19S/PA700 regulatory cap and a 20S proteolytic core 
and is the primary protein degradation system in the cell (Coux, Tanaka, & Goldberg, 1996). The 
19S/PA700 cap recognizes ubiquitylated substrates, removes ubiquitin chains, and unfolds the 
substrate to facilitate entry into the 20S core, where it is degraded into short peptides (Fig. 2). 
This process is initiated by the addition of polyubiquitin chains to distinct lysine residues on 
misfolded proteins through a series of enzymatic steps (Finley, 2009). The following enzymes 
permit the targeted and selective degradation of substrates: E1 (ubiquitin-activating enzyme), E2 
(ubiquitin-conjugating enzyme), and E3 (ubiquitin ligase) (Richly et al., 2005). E1 hydrolyzes 
ATP and forms a link between ubiquitin and itself, E2 receives ubiquitin from E1, and E3 binds 
both E2 and ubiquitin and transfers the ubiquitin to a specific lysine residues on the substrate 
(Richly et al., 2005).  Misfolded proteins with K48-linked ubiquitin chains are then directed to 
the proteasome by chaperone-co-chaperone complexes. In contrast, K63-linkages promote 
inclusion formation and facilitate preferential clearance of inclusions via autophagy (Tan et al., 
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2008). The process of ubiquitylation of substrates and their subsequent degradation through the 
proteasome is termed the ubiquitin proteasome system.  
The second protein degradation system, autophagy, is known to complement the 
ubiquitin proteasome system by degrading misfolded proteins as well as larger protein 
complexes or dysfunctional organelles through the action of lysosomes (Yang & Klionsky, 
2010). Autophagy consists of three distinct forms: macroautophagy, microautophagy, and 
chaperone-mediated autophagy (Yang & Klionsky, 2010). Macroautophagy is the best studied 
and entails the sequestration of cytosolic substrates by a double membrane structure termed an 
autophagosome (Fig. 2) (Yang & Klionsky, 2010).  The autophagosome then fuses with the 
lysosome and the contents are released for degradation. Microautophagy is the process of 
invagination of the lysosomal membrane and direct engulfment of cytosolic material (Yang & 
Klionsky, 2010). Finally, chaperone-mediated autophagy involves the Hsc70-mediated delivery 
of specific pentapeptide sequence (KFERQ)-bearing substrates, such as the hallmark Parkinson’s 
disease protein α-synuclein. These substrates are directed to the lysosome and translocated across 
the lysosomal membrane through the LAMP2A receptor (Fig. 2) (Kaushik & Cuervo, 2012; 
Yang & Klionsky, 2010).  
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Figure 2. Protein degradation pathways in the cell. Reprinted from “Molecular events underlying Parkinson’s 
disease – an interwoven tapestry,” by K. L. Lim and C. W. Zhang, 2013, Frontiers in Neurology, 4:33. Copyright 
2013 by Lim and Zhang.  Reprinted with permission.  
 
Neurodegenerative Mechanisms in Parkinson’s disease 
Accumulation of Misfolded Proteins 
All neurodegenerative disorders are characterized by the presence of intracellular 
aggregates, strongly suggesting ubiquitin proteasome system and autophagic dysfunction in these 
conditions. In Parkinson’s disease, the protein α-synuclein is especially prone to misfolding, 
causing a loss of its functional conformation. This misfolding exposes β sheet stretches prone to 
protein-protein interactions, thereby leading to the eventual formation of detergent-insoluble 
protein aggregations (Saxena & Caroni, 2011). The predominant modification of α-synuclein in 
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Lewy bodies is its selective and extensive phosphorylation at Ser129 (pSer129) (Anderson et al., 
2006; Fujiwara et al., 2002; Waxman & Giasson, 2008). It remains controversial whether the 
conformational changes and accumulation of this protein promote disease through a toxic gain or 
loss of function. Nevertheless, it is generally assumed that the smaller oligomer or protofibrillar 
form of this protein is responsible for cell toxicity, although the exact pathogenic mechanism still 
remains elusive. Mutant α-synuclein is known to induce the formation of filaments that bind and 
decrease the proteolytic activity of the 20S core particle of the proteasome (Lindersson et al., 
2004).  Heat shock proteins, such as Hsp/Hsc70, Hsp40, Hsp90, and small heat shock proteins 
can also be sequestered in aggregations as a consequence of failing to refold the misfolded 
protein to its native conformation, further negatively affecting protein homeostasis (Auluck, 
Chan, Trojanowski, Lee, & Bonini, 2002; Saxena & Caroni, 2011). The accumulation of 
ubiquitinated proteins, heat shock proteins, misfolded synuclein, and components of the ubiquitin 
proteasome system within Lewy bodies suggest that ubiquitin proteasome system dysfunction is 
strongly linked with the pathogenesis of Parkinson’s disease (Ii, Ito, Tanaka, & Hirano, 1997; 
Lennox, Lowe, Morrell, Landon, & Mayer, 1989; McNaught, Shashidharan, Perl, Jenner, & 
Olanow, 2002; Schlossmacher et al., 2002).  
Deficits in ubiquitin-proteasome activity further contribute to the loss of protein 
homeostasis in neurodegenerative diseases. For example, reductions in proteasome activity and 
levels of proteasomal subunits have been reported in the SNpc of sporadic Parkinson’s disease 
patients (McNaught, Belizaire, Isacson, Jenner, & Olanow, 2003; McNaught & Jenner, 2001; 
Tofaris, Razzaq, Ghetti, Lilley, & Spillantini, 2003). However, the strongest evidence regarding 
the role of the ubiquitin proteasome system in Parkinson’s disease can be found in studies 
showing that genetic mutations in components of this pathway cause dopaminergic 
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neurodegeneration. For example, autosomal recessive loss-of-function mutations in parkin, an E3 
ligase, are an established cause of familial Parkinson’s disease (Imai, Soda, & Takahashi, 2000; 
Shimura et al., 2000). In addition, the gene encoding ubiquitin carboxy-terminal hydrolase L1, 
which hydrolyses ubiquitin chains to free ubiquitin monomers, has been implicated in familial 
Parkinson’s disease (Leroy et al., 1998).  
Complimenting these genetic data, pharmacological studies have shown that injections of 
proteasome inhibitors into rats cause parkinsonian features, including Lewy body-like aggregates 
(Fornai et al., 2003; McNaught, Perl, Brownell, & Olanow, 2004; W. Xie et al., 2010).  In 
addition, proteasome inhibitors have been found to cause relatively selective degeneration of 
cultured dopamine neurons and formation of ubiquitin and α-synuclein positive inclusions 
(McNaught, Mytilineou, et al., 2002; Petrucelli et al., 2002; Rideout, Lang-Rollin, Savalle, & 
Stefanis, 2005; Sun et al., 2006). Specifically, the peptide aldehyde proteasome inhibitor MG132 
has been found to induce degeneration in the SNpc and to deplete dopamine levels in both cell 
culture and animal models (Sun et al., 2006). Thus, proteasome inhibition recapitulates many of 
the important behavioral and biochemical features of the disease, making it a useful tool for 
studying the pathogenesis of Parkinson’s disease or for testing neuroprotective therapies.   
Dysfunction in the autophagy-lysosomal pathway can also contribute to loss of protein 
homeostasis in neurodegenerative diseases. Neuron specific autophagy gene knockout mice have 
been found to develop intraneuronal aggregates and neurodegeneration (Hara et al., 2006; 
Komatsu et al., 2006). In addition, overexpression of α-synuclein impairs autophagy in 
mammalian cells and mice by inhibiting autophagosome formation (Winslow et al., 2010). 
Mutant α-synuclein may also impair chaperone-mediated autophagy by blocking the 
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translocation of substrates into the lysosome through the LAMP2A receptor (Cuervo, Stefanis, 
Fredenburg, Lansbury, & Sulzer, 2004; Martinez-Vicente et al., 2008).  
Oxidative Stress 
Reactive oxygen species are prevalent in the brain as the metabolism of excitatory amino 
acids and neurotransmitters causes high levels of these toxic byproducts (Uttara, Singh, 
Zamboni, & Mahajan, 2009). Mitochondrial dysfunction, protein misfolding, and dysregulation 
of the ubiquitin proteasome system can also contribute to the production of reactive oxygen 
species (Double, Reyes, Werry, & Halliday, 2010). Neurons are especially sensitive to free 
radicals as they are post-mitotic cells with an abundance of unsaturated lipids, which are 
particularly vulnerable to peroxidation and oxidative modification (Uttara et al., 2009). 
Additionally, the brain is especially susceptible to reactive oxygen species as it has lower levels 
of antioxidant defenses compared to other tissues, such as the liver.  
Oxidative stress is a common feature in neurodegenerative diseases and refers to an 
imbalance in the levels of reactive oxygen species and antioxidants. Reactive oxygen species can 
cause protein and DNA damage in addition to lipid peroxidation and are typically kept in check 
through antioxidant defenses such as glutathione, superoxide dismutases, catalases, and other 
mechanisms. Increased levels of oxidatively damaged proteins are present in the SNpc in 
Parkinson’s disease (Alam et al., 1997; Yoritaka et al., 1996). In addition, reactive oxygen 
species-related damage leads to a dysregulation of intracellular calcium signaling pathways. This 
can lead to cell death through downstream excitotoxic effects such as the activation of glutamate 
receptors and apoptosis in Parkinson’s disease (Uttara et al., 2009). Chronic oxidative stress can 
also interfere with autophagy, causing incomplete degradation of lysosomal cargo and thereby 
forming cross-linked products, such as lipofuscin, further impairing lysosomal function (Cuervo 
 18 
et al., 2005; Kiffin, Bandyopadhyay, & Cuervo, 2006; Terman & Brunk, 2004). Toxic products 
can then leak from the destabilized lysosomal membrane, thereby causing the release of 
lysosomal enzymes into the cytosol, a frequently observed event in dying neurons (Kiffin et al., 
2006; Terman & Brunk, 2004).  
The link between oxidative stress and neurodegeneration is also supported by toxin 
models, such as the herbicide paraquat, which can elicit dopaminergic degeneration and the 
motor deficits associated with Parkinson’s disease. Paraquat is a structural analog of 1-methyl-4-
phenylpyridinium (MPP+), another parkinsonism-inducing toxin (Langston, Ballard, Tetrud, & 
Irwin, 1983). Paraquat belongs to the class of redox cycling compounds capable of causing 
mitochondrial damage and increasing levels of reactive oxygen species such as the superoxide 
free radical (Castello, Drechsel, & Patel, 2007; Jenner, 2003). Epidemiological studies have 
suggested an association between chronic exposure to pesticides, particularly paraquat, and an 
increased risk for developing Parkinson’s disease (Gorell, Johnson, Rybicki, Peterson, & 
Richardson, 1998; Hertzman, Wiens, Bowering, Snow, & Calne, 1990; Liou et al., 1996; 
Semchuk, Love, & Lee, 1993). Moreover, in vivo studies have shown that chronic administration 
of paraquat in mice or rats causes a decrease in the number of dopaminergic neurons in the SNpc 
and striatal levels of dopamine (McCormack et al., 2002; Shimizu et al., 2003; Thiruchelvam et 
al., 2003).  
Protective Molecules Implicated in Protection Against Parkinson’s Disease 
Glutathione 
 Glutathione is a tripeptide containing glutamate, cysteine, and glycine. It is the most 
abundant nonprotein thiol in cells and participates in many important biological processes 
(Dickinson & Forman, 2002; Zeevalk, Razmpour, & Bernard, 2008). Glutathione is synthesized 
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in both neurons and glia and detoxifies oxidants and electrophiles (Dickinson & Forman, 2002; 
Dringen, 2000; Griffith, 1999). Oxidative stress emerges when the redox equilibrium favors 
higher levels of reactive oxygen species and lower glutathione levels, resulting in a decreased 
reducing environment within the cell (Genestra, 2007).  
As mentioned earlier, neurodegenerative disorders such as Parkinson’s disease are 
characterized by oxidative stress. In Parkinson’s disease, the SNpc exhibits increased levels of 
lipid peroxidation, iron content, and decreased glutathione levels (D. T. Dexter et al., 1991; D. T. 
Dexter et al., 1989; D. T. Dexter et al., 1994; Perry, Godin, & Hansen, 1982). Although a 30-
40% decrease of glutathione levels has been detected in this condition, there is no corresponding 
rise in oxidized glutathione levels (Sian, Dexter, Lees, Daniel, Jenner, et al., 1994; Sofic, Lange, 
Jellinger, & Riederer, 1992). Notably, the degree of disease severity has been correlated with the 
extent of glutathione loss (Riederer et al., 1989).  
Ceruloplasmin  
 Ceruloplasmin is a multi-copper enzyme ferroxidase found in a free, secreted form as 
well as a bound glycosylphosphatidylinositol (GPI)-anchored form in astrocytes in the central 
nervous system (Roeser, Lee, Nacht, & Cartwright, 1970). Ceruloplasmin is essential in iron 
homeostasis and has potent antioxidant activity (Ayton et al., 2013; Harris, Durley, Man, & 
Gitlin, 1999; Roeser et al., 1970). This multicopper ferroxidase facilitates cellular iron export by 
oxidizing toxic ferrous iron to ferric iron at the cell surface for incorporation into the iron 
transporter transferrin, thereby reducing the production of reactive oxygen species through the 
harmful Fenton reaction (Hellman & Gitlin, 2002). Ceruloplasmin ferroxidase activity also 
increases the stability of the iron export transporter, ferroportin, on the cell membrane (De 
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Domenico et al., 2007). As one might expected, many studies have supported a protective role 
for ceruloplasmin in neurodegenerative diseases (Texel, Xu, & Harris, 2008).  
Defects in ceruloplasmin activity have been linked with brain iron accumulation and 
neurodegenerative lesions (Jeong & David, 2003). In addition, individuals carrying one mutant 
ceruloplasmin allele are at increased risk for Parkinson’s disease (Hochstrasser et al., 2004). 
There is a significant loss of ceruloplasmin ferroxidase activity in the cerebrospinal fluid, serum, 
and SNpc in Parkinson’s disease (Boll, Alcaraz-Zubeldia, Montes, & Rios, 2008; Boll, Sotelo, 
Otero, Alcaraz-Zubeldia, & Rios, 1999; Jin et al., 2011; Olivieri et al., 2011; Torsdottir, 
Kristinsson, Snaedal, Sveinbjornsdottir, et al., 2010; Torsdottir, Sveinbjornsdottir, Kristinsson, 
Snaedal, & Johannesson, 2006). Low serum ceruloplasmin levels correlate with an early age of 
onset of Parkinson’s disease and with iron deposits in the SNpc (Bharucha, Friedman, Vincent, 
& Ross, 2008; Martinez-Hernandez et al., 2011). Iron deposits can promote conformational 
changes in α-synuclein, thereby contributing to Lewy body formation and to the pathogenesis of 
Parkinson’s disease (Graham, Paley, Grünewald, Hoggard, & Griffiths, 2000). Thus, iron 
chelation, such as with the drug deferiprone, has potential as a therapeutic strategy for 
Parkinson’s disease (Molina-Holgado, Gaeta, Francis, Williams, & Hider, 2008). This is 
consistent with the observation that iron homeostasis disorders present clinically with 
parkinsonian symptoms (Crichton, Dexter, & Ward, 2011). For example, aceruloplasminemia–a 
rare genetic disorder in which mutations abolish functional ceruloplasmin–presents with 
parkinsonism as well as cognitive loss and cerebellar and retinal degeneration (McNeill, 
Pandolfo, Kuhn, Shang, & Miyajima, 2008). 
 In addition to the clinical studies mentioned above, ceruloplasmin has been found to 
mitigate pathology in experimental Parkinson’s disease (Hineno, Kaneko, Yoshida, & Ikeda, 
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2011; Kaneko, Hineno, Yoshida, & Ikeda, 2008).  Ceruloplasmin knockout mice exhibit 
neuronal loss in the SNpc that can be mitigated with iron chelation (Ayton et al., 2014).  
Furthermore, ceruloplasmin mitigates neurodegeneration induced in mice by the dopaminergic 
neurotoxin MPTP and blunts the toxic accumulation of iron in the SNpc (Ayton et al., 2014).  
Aging and Parkinson’s Disease  
Based on numerous epidemiological studies, aging is acknowledged as the greatest risk 
factor for Parkinson’s disease (Bennett et al., 1996; Morens et al., 1996; Tanner & Goldman, 
1996). However, studies have shown that the neurochemical and morphological changes 
associated with aging are distinct from the pathological patterns evident in Parkinson’s disease 
(Fearnley & Lees, 1991; Gibb & Lees, 1991; Kish, Shannak, Rajput, Deck, & Hornykiewicz, 
1992). For example, aging humans exhibit little or no loss of SNpc dopaminergic neurons, a 
hallmark characteristic of Parkinson’s disease (Alladi et al., 2009; Kubis et al., 2000). A lack of 
age-related dopaminergic neuron loss has also been verified in the non-human primate brain, 
although expression of the phenotypic marker tyrosine hydroxylase may be lowered with aging 
(McCormack et al., 2004).  
The activity of the ubiquitin proteasome system and autophagy decreases with age in 
almost every tissue in old organisms (Cuervo et al., 2005). Moreover, small heat shock proteins 
and the constitutive Hsc70 are elevated but induction of Hsp70 is impaired in the aging brain 
(Fargnoli, Kunisada, Fornace, Schneider, & Holbrook, 1990; Schultz et al., 2001; Sóti & 
Csermely, 2000). This dysfunction may play a role in the failure of the intracellular quality 
control systems observed in neurodegenerative disorders with age.  
Increased levels of oxidative stress are a cornerstone of the aging process and 
neurodegenerative disease. Oxidative stress increases with age in part due to a widening 
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imbalance between the antioxidant defense system and oxidants in the cell, which progresses 
exponentially in the last trimester of life (Agarwal & Sohal, 1994). Glutathione content decreases 
with age in many tissues from different animal species though the mechanism is unclear (Liu, 
Wang, Shenvi, Hagen, & Liu, 2004). In addition, dysfunctional mitochondria generate increasing 
levels of reactive oxygen species with age (Brunk & Terman, 2002a, 2002b). These 
dysfunctional organelles are removed from the cell through the lysosomal system, generating 
high levels of the autofluorescent pigment lipofuscin (Brunk & Terman, 2002b). Lipofuscin, also 
known as the “age pigment”, accumulates in many brain regions during aging and is thought to 
reflect increasing age-related mitochondrial damage and subsequent lysosomal degredation 
(Terman & Brunk, 1998; Terman, Gustafsson, & Brunk, 2006). It is important to note that Braak 
reported that the allocortex develops lipofuscin pigments at a faster rate than the neocortex (H. 
Braak, Del Tredici, Schultz, & Braak, 2000; H. Braak, Rub, Schultz, & Del Tredici, 2006). 
During aging, serum ceruloplasmin expressed greater oxidative modifications that induce 
conformational changes, thereby reducing the functionality of the ferroxidase in older animals 
(Musci, Bonaccorsi di Patti, Fagiolo, & Calabrese, 1993). Thus, the reduction in ceruloplasmin 
activity in the cerebrospinal fluid in Parkinson’s disease may reflect increased protein aging and 
elevated levels of oxidative stress.  In sum, the studies discussed here all provide evidence for a 
strong link between aging and the pathogenesis of Parkinson’s disease.   
In conclusion, Parkinson’s disease is an age-related disorder characterized by protein 
misfolding, oxidative stress, and the staged appearance of Lewy pathology across various brain 
regions. The staged appearance of protein inclusions may be attributable to the spread of 
synucleinopathy across neuroanatomical circuitry as well as selective vulnerability differences. 
These latter two possibilities are not mutually exclusive and probably converge to determine 
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whether or not a given cell will develop protein inclusions and perhaps degenerate. The major 
goal of the present study was to determine whether two large brain areas, the allocortex of the 
temporal lobe and the neocortex of the frontal and parietal lobes exhibit intrinsic vulnerability 
differences that parallel the staged appearance of protein inclusions in allocortex followed by 
neocortex. If this hypothesis were supported, it would be consistent with the notion that selective 
vulnerability plays an important role in the topographical appearance of Lewy pathology in 
Parkinson’s disease and would contribute a new model for the study of intrinsic vulnerability 
differences in experimental Parkinson’s disease. Furthermore, the identification of factors that 
mediate selective vulnerability differences might accelerate the discovery of new targets and/or 
treatments for Parkinson’s disease.  
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Materials and Methods  
Animals  
Animal use was approved by the Duquesne University Institutional Animal Care and Use 
Committee and carried out in accordance with the principles outlined in the NIH Guide for the 
Care and Use of Laboratory Animals. Female Sprague Dawley rats were fed ad libitum and 
singly housed in a room maintained at a constant temperature with a 12 hr light/dark cycle. Rats 
were sacrificed at 2-3.9 (n=6), 4-6 (n=6), 8-9 (n=6), 16-18.9 (n=5), and 19-22 (n=6) months of 
age for the aging study. These rats formed part of an in-house breeding colony designed to 
generate rat pup tissue for postnatal cultures. Tissue was dissected according to the definitions in 
the Paxinos rat atlas (Paxinos & Watson, 1998).  
Chemicals and antibodies 
Primary and secondary antibodies are listed in supplementary tables in the Appendix. 
Omission of primary antibodies from the assays always resulted in loss of signal. Proteasome 
inhibitors MG132 (EMD Millipore, Billerica MA, Cat. no. 474790) and PSI (Tocris, 
Minneapolis, MN, Cat. no. 4045) were stored at – 20 and – 80 oC, respectively, as 10 mM stock 
solutions in dimethyl sulfoxide (DMSO). H2O2 was purchased from Fisher Scientific (Pittsburgh, 
PA, Cat. no. H324) and stored at 4oC as an 882 mM stock. The oxidative toxin paraquat (Sigma-
Aldrich, St. Louis, MO) was dissolved in PBS (100 mM) and stored at -80 oC. Hsp70/Hsc70 
activity was inhibited with the previously characterized compounds VER155008 (R&D Systems, 
Minneapolis, MN;  Chatterjee et al., 2013; Massey et al., 2010; Saykally et al., 2012; Schlecht et 
al., 2013) and MAL3-101 (Adam et al., 2014; Braunstein et al., 2011; Hatic, Kane, Saykally, & 
Citron, 2012; Huryn et al., 2011; Kilpatrick et al., 2013). Hsp70 activity was enhanced with 115-
7c (MAL1-271) (Kilpatrick et al., 2013; Wisen et al., 2010).  Heme oxygenase 1 was inhibited 
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with tin protoporphyrin (SnPP) (Drummond & Kappas, 1981). Preformed α-synuclein fibrils 
(5mg/mL) were made as previously reported (Volpicelli-Daley, Luk, & Lee, 2014b). Fibrils were 
sonicated in a waterbath for 30 sec at room temperature immediately before use (Fisher 
Scientific FS6 Ultrasonic Cleaner Model B200). 
Primary Cultures 
All efforts were made to minimize animal suffering and to reduce the number of animals 
sacrificed. Animal use was approved by the Duquesne University Institutional Animal Care and 
Use Committee (protocol number 1006-06), and carried out in accordance with the principles 
outlined in the NIH Guide. Neocortical tissue and tissue from entorhinal allocortex, piriform 
allocortex, hippocampal allocortex, and olfactory bulb were dissected with microforceps from 
the brains of postnatal day 1 or 2 Sprague Dawley rats (Charles River, Wilmington, MA) and 
incubated in 10 Units/mL papain (Sigma-Aldrich, Cat. no. P3125) for 30 min. Following a 
second incubation in 10% type II-O trypsin inhibitor (Sigma-Aldrich, Cat. no. T9253), cells were 
triturated in Basal Medium Eagle (Sigma-Aldrich, Cat. no. B1522) containing 10% bovine calf 
serum (BME/BCS, HyClone Thermo Scientific, Logan, UT, Cat. no. 2151,) supplemented with 
35 mM glucose (Sigma-Aldrich, Cat. no. G8769), 1 mM L-glutamine (Gibco, Life Technologies, 
Cat. no. 25030-081), 50 Units/mL penicillin, and 50 µg/mL streptomycin (Gibco, Life 
Technologies, Cat. no. 15140-122). Dissociated cells were then seeded in Opti-MEM (Gibco, 
Life Technologies, Cat. no. 51985-034) supplemented with 20 mM glucose at a plating density 
of 80,000-100,000 cells/well in 96-well plates or 2.35-3 million cells/well in 6-well plates 
(Corning Costar, Corning Incorporated, Corning, NY). All plates were precoated with poly-D-
lysine (1 µg/mL) and laminin (1.88 µg/mL, BD Biosciences), washed, and dried prior to seeding. 
After a 2-hour incubation of plated cells in Opti-MEM, a full media change was performed 
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exchanging Opti-MEM for BME/BCS or Neurobasal-A media (Gibco, Life Technologies) 
supplemented with 2% v/v serum-free B27 (Gibco, Life Technologies) and 2 mM L-glutamine 
(Data in Figures 3-9 were from experiments conducted in BME/BCS whereas data in Figures 10-
22 were from experiments conducted in Neurobasal-A media). Cells were treated on day-in-vitro 
2 (DIV2). 
Primary astrocytes were harvested from neocortex and allocortex. For the astrocyte 
cultures, entorhinal cortex was combined with piriform cortex to generate sufficient astrocytic 
material. Briefly, tissue was dissociated in Dulbecco’s modified eagle medium (Gibco, Life 
Technologies) supplemented with 10% fetal clone III (Hyclone, Thermo Scientific) and 1% 
penicillin/streptomycin (Gibco, Life Technologies) after incubation with 0.25% trypsin with 
EDTA (Invitrogen, Life Technologies). After 7-9 days, cultures were placed overnight on an 
orbital shaker at 260 rpm.  Two to three days later, astrocytes were passaged and seeded onto 
plates. Astrocyte cultures were treated with toxins on DIV5 and assayed on DIV7. 
Validating dissections of neo- and allocortex 
 In order to visualize the full anatomical extent of our microdissections, we dissected 
neocortex and allocortex from postnatal day 1 brains and then fixed the dissected brains in 4% 
paraformaldehyde. Fixed brains were cryoprotected in 30% sucrose in phosphate-buffered saline 
(PBS) and cut at a thickness of 50 µm in the sagittal plane on a microtome (Thermo Scientific 
Microm HM 450, Walldorf, Germany). Sections were stained with infrared DRAQ5 (1:2000; 
BioStatus Limited, Leicestershire, UK) diluted in PBS with 0.3% Triton-X 100 (ACROS, Geel, 
Belgium) for permeabilization. Washed and dried slides were imaged at 21 µm resolution on an 
Odyssey Infrared Imager (LI-COR, model number 9201-01). 
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Toxin and inhibitor treatments 
Because these cultures are initiated postnatally, the cortical neurons express high levels 
of punctate synaptic markers synaptophysin and synaptogyrin 3 already within a few days of 
culturing (R.K. Leak, unpublished observations). Treatments were begun on DIV2, 48 hours 
after plating). Cells were treated with 10× stocks of MG132, PSI, paraquat, or H2O2 added to 
BME/BCS III along with 2.5 µM cytosine arabinofuranoside to suppress, but not eliminate, glial 
proliferation or Neurobasal-A media supplemented with 2% v/v serum-free B27 and 2 mM L-
glutamine. Twenty-four hours later (DIV3) fresh media was added. Multiple viability assays 
were then performed on DIV4 (see below). For inhibition of autophagy, 10× stocks of 
ammonium chloride (NH4Cl, 20 mM; Acros Organics, Somerset, NJ) or wortmannin (50 nM; 
Sigma-Aldrich) were applied in conjunction with MG132 on DIV2 and freshly added on DIV3. 
N-acetyl cysteine (3 mM; Acros Organics), VER155008, MAL3-101, 115-7c, SnPP, and 
rapamycin (0.025 - 3.2 µM; Research Products International, Mt. Prospect, IL) were applied with 
this same protocol. For α-synuclein fibril treatments, cultures were treated with α-synuclein 
fibrils in a full media exchange on DIV2 and then fixed on DIV9.  
Immunocytochemistry and viability assays 
In order to gain a comprehensive view of cellular fitness, we used two independent rapid, 
unbiased assays, one for the neuronal marker MAP2 (see below) and one for ATP. ATP levels 
were assessed with a modification of the luciferase-based Cell Titer Glo assay (25 µl reagent in 
50 µl media; Promega Inc., Madison, WI). Luminescence was measured within 15 minutes on a 
microplate reader (VICTOR3 1420 multilabel counter; PerkinElmer, Waltham, MA). 
For MAP2 immunocytochemistry, non-specific secondary binding was first minimized 
by blocking in a fish serum solution (Odyssey Block, LI-COR) diluted 1:1 in phosphate buffered 
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saline (PBS) with 0.3% Triton-X 100. This was followed by serial incubations in primary 
antibodies (2 hr or overnight) and secondary antibodies (1 hr) in the Odyssey Block:PBS solution 
with PBS washes in between steps. Infrared secondary antibody binding (700 and 800 nm) was 
visualized and quantified with Odyssey software (Version 3.0, LI-COR) on the Odyssey Infrared 
Imager. Neuronal and astrocyte cultures were stained with Hoechst (10 µg/ml Hoechst 33258, 
bisBenzimide) in phosphate-buffered saline with 0.3% Triton-X for 15-30 min for blinded cell 
counts. Astrocytes were also stained with the infrared nuclear stain DRAQ5 (1:10,000, 700 nm; 
Biostatus, Shepshed, Leicestershire, UK) and assayed on the Odyssey Imager to validate the 
Hoechst cell count data. In addition, cultures were immunocytochemically stained for the 
neuronal markers MAP2 and β-tubulin III, the astrocyte marker glial fibrillary acidic protein 
(GFAP), and/or the synaptic protein synaptophysin in the visible-range and photographed on an 
epifluorescence microscope for higher resolution images (Advanced Microscopy Group, Model 
#AMF-4301-US, Bothell, WA). MAP2+ neurons, GFAP+ astrocytes, and/or Hoechst-stained 
nuclei were then counted by a blinded observer at 20× magnification in a 0.213 mm2 field of 
view (three fields per well). 
For cultures treated with α-synuclein fibrils, inclusions were visualized by 
immunostaining for the aggregated form of α-synuclein (pSer129) (Anderson et al., 2006; 
Fujiwara et al., 2002; Hasegawa et al., 2002; Saito et al., 2003). Images were captured on an 
epifluorescence microscope as described previously. Hoechst-stained nuclei and α-synuclein+ 
inclusions were quantified by a blinded observer using ImageJ software (National Institutes of 
Health, Bethesda, MD). The analyze particles command was used to count and measure objects 
by scanning the image until the edge of an object was located. The software then outlined the 
object and displayed the following measurements: particle count, average particle size, and area 
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fraction. Area fraction refers to the percentage of pixels in the image that have been segmented 
above background. “Background” was defined at the same level for all microphotographs. 
Western immunoblots on in vitro and in vivo lysates 
Cultured cells were incubated for 10 min with Cell Lysis Buffer (Cell Signaling, 
Danvers, MA) supplemented with protease inhibitors (Sigma, Cat. no. P8340) and 10 mM 
sodium fluoride (Leak, Castro, Jaumotte, Smith, & Zigmond, 2010) 24h after toxin treatments. 
For cultures treated with α-synuclein fibrils, lysates were collected on DIV9. Scraped cells were 
sonicated for 20 pulses at 1 sec each (Misonix Inc. Model XL2020 Farmingdale, NY). Protein 
content in total cell lysates was quantified by the bicinchoninic acid method according to the 
manufacturer’s instructions (ThermoScientific). Equal amounts of protein (10-30 µg) were then 
separated on 10% polyacrylamide gels by standard sodium dodecyl sulfate gel electrophoresis 
and transferred to Immobilon-FL polyvinylidene fluoride membranes (EMD Millipore). 
Membranes were incubated in the Odyssey Block fish serum solution or 5% milk in Tris 
buffered saline (TBS) for 30-60 min at room temperature. All membranes were then incubated in 
primary antibodies in 50% Odyssey block diluted in PBS with 0.1% Tween or 5% bovine serum 
albumin in TBS overnight at 4oC on a shaker. The following day, blots were washed three times 
in PBS or TBS and incubated in the appropriate secondary antibody in the same diluent for 1 
hour at room temperature. Washed blots were then visualized and quantified on the Odyssey 
Infrared Imager. All proteins were expressed as a fraction of β-actin, α-tubulin, or GAPDH to 
control for differences in protein loading across treatment groups. As multiple proteins were 
probed on the same blots, the identical loading controls are presented twice in some figures. 
For in vivo immunoblotting, female Sprague-Dawley rats (Charles River) were sacrificed 
as a group at 2-3.9, 4-6, 8-9, 16-18.9, and 19-22 months of age. Tissue was weighed, sonicated in 
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the abovementioned Cell Lysis Buffer (20 µL buffer per mg tissue), and standard 
immunoblotting as described above was then performed. 
Proteasome activity 
Proteasome activity was assessed 30 min after MG132 treatment on DIV2 according to 
the manufacturer’s instructions (Cayman Chemical Company, Ann Arbor, MI, USA). In this 
assay, Suc-LLVY-AMC generates a fluorescent product when cleaved by the proteasome. 
Fluorescent intensity was read at 355 nm excitation and 460 nm emission (VICTOR3 1420 
multilabel counter). Proteasome inhibitors epoxomicin and the tea polyphenol epigallocatechin 
gallate were used as negative controls during the assay but did not lead to greater loss of 
proteasome activity than MG132. In addition to negative controls, Jurkat cell lysates were used 
as a positive control as this cell type exhibits high basal levels of proteasome activity. Nuclear 
DRAQ5 and MAP2 immunostaining on parallel plates was used to ensure equal protein content 
across treatment groups. 
Glutathione assay 
Glutathione levels were measured in neo- and allocortical tissue as a function of age. 
Dissected tissue was weighed and sonicated in PBS containing 2 mM EDTA (100 µL solution 
per mg tissue). The manufacturer’s instructions for the GSH-Glo assay for reduced glutathione 
were then followed (Promega Inc. Cat. no. V6911).  This luminescent assay is based on 
conversion of a luciferin derivative into luciferin in the presence of glutathione and is catalyzed 
by glutathione-S-transferase. Data for each animal were collected in duplicate and expressed as 
relative luminescence units. 
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Thioflavin-S Staining 
After fixation, hippocampal cultures were stained with 0.05% Thioflavin S (Sigma-
Aldrich, St. Louis, MO) in phosphate buffered saline (PBS) at room temperature for 8 minutes 
and then washed 3 × 10 min with PBS. Images were captured with an epifluorescent microscope 
as stated above. Hoechst-stained nuclei and Thioflavin S+ amyloid formations were quantified 
using ImageJ software as described above, using integrated density (product of area and mean 
gray value) as the measurement output. 
Triton X-100 detergent extraction 
Hippocampal cultures were treated with α-synuclein fibrils on DIV2. On DIV9, 
hippocampal neurons were fixed with 4% paraformaldehyde in the presence of 1% Triton X-100 
for 20 min at room temperature followed by 3 × 200 µL PBS washes. Cells were stained with 
Hoechst and pSer129 antibodies and images were captured with an epifluorescent microscope as 
described above. 
Statistical Analyses 
Data are presented as the mean and SEM from 3-6 animals in vivo or a minimum of 3 
independently run experiments in vitro. With the exception of Western blotting, each in vitro 
experimental group was run in three microplate wells, from which data were pooled to yield one 
average value for that experiment.  Data were analyzed by one-, two-, or three-way ANOVA 
followed by the Bonferroni post hoc correction (Graphpad Prism Version 5d or SPSS Version 
20, Armonk, NY).  For semi-quantitative Western blotting data, the LSD post hoc test was 
employed. For data with only two groups, the two-tailed Student’s t-test was employed. The 
Grubb’s outlier test was performed once on all the data and bands with fluorescent lint or air 
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bubbles were excluded from the Western blot analyses. Differences were deemed significant 
only when p ≤ 0.05. 
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Chapter 1 
Rationale 
All neurodegenerative diseases are characterized by severe disturbances in protein 
homeostasis, with the rate of formation of misfolded proteins out of balance with their clearance 
(Uversky, 2009; Walker & LeVine, 2000; Walker, Levine, Mattson, & Jucker, 2006). As a result 
of loss of protein homeostasis, all neurodegenerative disorders are also characterized by hallmark 
protein inclusions, such as α-synuclein+ Lewy bodies and Lewy neurites in Parkinson’s disease. 
The neuroanatamist Heiko Braak used the distribution of α-synuclein+ protein aggregations to 
categorize Parkinson’s disease into 6 distinct stages and hypothesized that the topographical 
spread of protein inclusions reflects the symptomatic progression of the disease (H. Braak, Del 
Tredici, Bratzke, Hamm-Clement, Sandmann-Keil, & Rüb, 2002; H. Braak, Del Tredici, Rüb, et 
al., 2003; Dickson, Uchikado, Fujishiro, & Tsuboi, 2010; Jellinger, 2011). Several studies have 
found that the presence of cortical inclusions correlates with cognitive impairments in 
Parkinson’s patients (H. Braak, Rub, Jansen Steur, Del Tredici, & de Vos, 2005; Hurtig et al., 
2000; Jellinger, 2006). According to the Braak staging scheme, the cortical spread of aggregated 
α-synuclein begins in the temporal meso- and allocortex whereas the primary sensorimotor 
regions of the frontal and parietal neocortex are affected only at the very end stages of the 
disorder. This observation suggests that the allocortex is more vulnerable to protein misfolding 
stress than the neocortex, although this had yet to be tested in an experimental model. Thus, we 
developed a novel in vitro model of neo- and allocortex, using primary cells from the postnatal 
rat pup brain and treated these primary cultures in parallel with toxins that elicit protein-
misfolding and oxidative stress. First, the primary culture model was characterized and the 
linearity and reproducibility of all our viability assays was assessed.  
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Specific Aim 1a: Develop novel neo- and allocortical primary neuron culture models and 
establish multiple independent viability assays for metabolic fitness and structural integrity. 
Results 
Characterization of Primary Neo- and Allocortical Cultures 
Primary sensorimotor neocortex and entorhinal allocortex were dissected from postnatal 
day 1 or 2 rat pups and plated at 100,000 cells per well in BME/BCS III media. Cells were 
treated with 2.5 µM cytosine arabinofuranoside to suppress, but not eliminate, glial proliferation 
on DIV2. Hoechst staining for nuclei and immunostaining for the neuronal marker MAP2 in neo- 
and allocortical cultures revealed that the majority of cells present are indeed MAP2+ (Fig. 3C, 
F). The long stemmed arrows in Figure 3 point to small, condensed nuclei that may be 
undergoing apoptosis and may therefore no longer express the MAP2 phenotype. The 
arrowheads point to large, flat nuclei, which may be astrocytic based on staining for GFAP (data 
not shown) (Fig. 3A, D). Nearly 75% of both neo- and allocortical cultures were found to be 
MAP2+ (Fig. 3G). However, allocortical cells survived in BME/BCS III media at a higher 
density than neocortical cells, even though both were initially plated in parallel at the same 
density. Thus, allocortex had higher MAP2 levels in In-Cell Western analyses, as illustrated in 
the photomicrograph insert (Fig. 3H, I). In addition, allocortex also exhibited higher levels of 
ATP because of higher cell density. Photomicrographs of our dissections are illustrated in Figure 
3J to show the anatomical boundaries of the areas harvested for study. For this image, postnatal 
day 1 rat brains were fixed in paraformaldehyde following the fresh tissue dissections, cut in the 
sagittal plane, and then stained with the nuclear marker DRAQ5 and imaged on an Odyssey 
imager. 
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Figure 3. Characterization of in vitro model. A-F: Plates were immunostained on DIV4 for the neuronal marker 
microtubule associated protein 2 (MAP2, shown in red). Nuclei were stained blue with Hoechst. Merged images 
reveal that the majority of the Hoechst-stained nuclei were neuronal. However, arrowheads point to large nuclei that 
were possibly glial. Long stemmed arrows point to condensed, potentially apoptotic nuclei that may have lost their 
neuronal phenotype. G: Blind cell counts revealed that nearly 75% of neocortical and allocortical Hoechst-positive 
cells expressed the MAP2 neuronal phenotype. H and I: Basal survival on DIV4 was measured by an infrared In-
Cell Western assay for MAP2 and by the Cell Titer Glo assay for ATP. Both assays revealed that allocortex 
survived in vitro conditions at approximately twice the rate of neocortex. A grayscale inset of a representative 
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infrared MAP2 stain of neo- versus allocortical neurons is included in H. Shown are the mean and standard error of 
the mean of at least 3 independent experiments. ** p ≤ 0.01 or *** p ≤ 0.001 by the two tailed t-test. J: Brains were 
fixed following tissue dissections, cut in the sagittal plane, and stained for the infrared nuclear marker DRAQ5. 
Neocortical dissections (arrow) were centered in primary motor and sensory cortex (Ctx), dorsal to hippocampus 
(HP) and caudoputamen (CP). Allocortical dissections (arrow) were centered much more laterally in the brain 
ventral to hippocampus in the entorhinal and piriform cortices. Reprinted from “Neocortex and Allocortex Respond 
Differentially to Cellular Stress In Vitro and In Vivo,” by J. Posimo, A. Titler, H. Choi, A. Unnithan, and R. Leak 
2013, PLoS ONE, 8(3): e58596. doi:10.1371/journal.pone.0058596. Copyright 2013 by Posimo et al.  Reprinted 
with permission. 
 
Verifying Viability Assay Linearity and Sensitivity in Neo- and Allocortical Cultures  
In order to establish multiple independent and unbiased viability assays, rat primary 
neuronal cultures from the cerebral cortex were stained for the neuronal marker MAP2 (Fig. 4B) 
and the nuclear and cytoplasmic stain DRAQ5 + Sapphire (Fig. 4A). ATP levels were assessed 
with the Cell Titer Glo assay (Fig. 4C). Signal strength was then plotted as a function of plating 
density. The DRAQ5 + Sapphire assay was the least sensitive of all three assays as there was 
little difference in signal between 100,000 and 200,000 cells per well in the 700 nm channel (Fig. 
4A). However, it should be noted that we only plated primary neuronal cells at 100,000 per well 
for subsequent experiments, a density at which DRAQ5 signal was not saturated. All three assays 
exhibited a linear correlation between plating density and signal strength, as noted by the R2 
values or the coefficient of determination (two tailed p ≤ 0.05). Furthermore, changes in 
luminescence or signal strength were proportional to changes in cell number (ie, 50,000 cells 
have 50% of the signal of 100,000 cells). These observations demonstrate that the assays are 
sufficiently sensitive to changes in cell density at the plating densities employed. 
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Figure 4:  Linearity and sensitivity of viability assays in primary postnatal neurons (A, B, C). Signal strength for 
each assay is plotted as a function of plating density. Insets show representative infrared images of the DRAQ5 + 
Sapphire (A), or MAP2 (B) stain and raw intensity values are listed for each image. Note that the original infrared 
images were pseudocolored red (700 nm) or green (800 nm). Each experiment was performed in triplicate wells and 
repeated 3 times for DRAQ5 + Sapphire, 4 times for MAP2, 4 times for ATP. The data from the 3 wells were 
averaged for one final value for each experiment. The mean and SEM of these 3-4 final values is shown in the 
graph. Note that the DRAQ5 + Sapphire values exhibit low standard deviations so that SEM bars are not apparent. 
The R2 coefficient of determination and two tailed p value assessing the significance of the correlation are also 
illustrated for each measure. Data were analyzed in Graphpad Prism (Version 6.0). Adapted from “Viability Assays 
for Cultured Cells,” by J. Posimo, A. Unnithan, A. Titler, H. Choi, Y. Jiang, and S. Pulugulla. 2013, J. Vis. Exp. 
(83), e50645, doi:10.3791/50645. Copyright 2014 by Posimo et al.  Adapted with permission. 
 
Reproducibility of the Viability Assays 
In order to measure the reproducibility of the assays within experiments (intraplate 
variability), we plotted the raw data from two replicate wells from experiments where cortical 
neurons were treated with H2O2 (Fig. 5A-C). Additionally, in order to measure reproducibility 
across experiments (interplate variability), we plotted the mean of triplicate wells from two 
separate plates (Fig 5D-F). The regression analyses illustrate a significant correlation between 
signal in replicate wells and across independent experiments for every measure. Primary 
neuronal cultures stained for MAP2 had the highest interplate variability.  This might be 
attributed to the freezing and reuse of the MAP2 antibody or variability in the culturing 
procedure itself. 
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Figure 5: Intra- and inter-experimental variability in viability assays. All individual experiments were run in 
triplicate wells. Raw data from the second two wells within each group were plotted as replicates 1 and 2 to measure 
reproducibility within the plates (A-C). Data from the same groups in two independent experiments (the mean of the 
triplicate wells) were plotted as plate 1 and plate 2 to measure reproducibility across plates (D-F). The R2 coefficient 
of determination and two tailed p value assessing the significance of the correlation are also illustrated for each 
measure. Data were analyzed in Graphpad Prism (Version 6.0). Adapted from “Viability Assays for Cultured Cells,” 
by J. Posimo, A. Unnithan, A. Titler, H. Choi, Y. Jiang, and S. Pulugulla. 2013, J. Vis. Exp. (83), e50645, 
doi:10.3791/50645. Copyright 2014 by Posimo et al.  Adapted with permission. 
 
Discussion 
Neo- and allocortex were microdissected from postnatal day 1-2 rat pup brains and used 
for our in vitro model. Nearly 75% of neo- and allocortical cells were found to be MAP2+ when 
plated in BME/BCS III media supplemented with cytosine arabinoside to suppress glial growth. 
Relative to early embryonic cultures this may seem low, but postnatal studies typically report 50-
80% neuronal purity or do not express neurons as a function of total cell numbers (Olivieri et al., 
2011; Wang et al., 2006). The remaining large, flat nuclei may be astrocytic as they stain for 
glial fibrillary acidic protein (data not shown). Astrocyte genesis is known to peak in the early 
neonatal period (Miller & Gauthier, 2007), so it is not surprising that postnatal cultures have 
A B C
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more astrocytes than embryonic cultures. Glia play an important role in supporting neuronal 
function and modifying disease processes and are always present in vivo. Thus, having some glia 
present in our cultures is appropriate (Halliday & Stevens, 2011).  
One potential caveat in our in vitro system was the higher basal survival in allocortical 
cultures. Higher allocortical cell density might increase the concentration of neuroprotective 
trophic factors in the extracellular media, leading to an increase in resilience. However, as shown 
in Specific Aim 1b, we observed opposite results with the oxidative toxin H2O2 and the 
proteasome inhibitor MG132, with allocortex being more vulnerable to MG132 but less 
vulnerable to H2O2, suggesting that cell density per se does not drive cell vulnerability in this 
model. Additionally, we switched to Neurobasal-A media in subsequent experiments, in which 
neo- and allocortical cultures survived equally well and exhibited similar vulnerabilities to 
oxidative stress and proteotoxicity.  
Another potential caveat of our in vitro system was the possibility we had selected 
specific subpopulations of neo- and allocortical neurons that can survive the culturing process, 
thereby removing more vulnerable populations and leading to differential stress resistance. 
However, if this were true, it would be unlikely to observe the same density of MAP2+ cells 
(expressed as a function of Hoechst+ cell numbers) in neo- and allocortical cultures (Fig. 3G). 
Nonetheless, further studies to investigate phenotypically distinct subpopulations in these two 
brain regions in vitro and in vivo are highly warranted.  
After characterizing the in vitro model, the linearity and reproducibility of the viability 
assays were assessed.  As expected, the signal from all three viability assays was linearly 
correlated with plating density.  For primary neurons, the DRAQ5+Sapphire stain was the least 
sensitive measure at high plating densities. Nonetheless, all three assays were well in proportion 
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to cell number when cultures were plated at 100,000 cells per well or below. As postnatal 
neurons are not known to replicate, we know that our measurements are not saturated or out of 
the dynamic range of the assay. Previous work is in agreement with our studies that multiple 
viability assays are more robust measures of cellular fitness than assays of one feature alone such 
as cell counts. (Gilbert et al., 2011).  
For the vast majority of our studies, these three assays are used as an alternative to 
manual cell counts of nuclear numbers. Cell counting, when conducted properly and in blinded 
fashion, is an accurate means of assessing viability. If the ATP and infrared assays fail the 
linearity test, then manual cell counts are more appropriate. Nevertheless, some caveats of the 
latter method must be considered. For example, choosing a threshold nuclear diameter to 
differentiate between a live and dead cell is an arbitrary measurement as it is unknown from 
nuclear diameter alone when an irreversible apoptotic cascade begins.  In comparison, our 
infrared assays do not depend on a continuous function such as nuclear diameter when making 
the distinction between live and dead cells. Instead, they avoid this pitfall by treating all cells still 
attached to the plate after fixation as live and all cells that have washed off as dead. 
Manual cell counts also tend to only sample a small fraction of the well, which can lead 
to sampling bias and high standard deviations of the data. In contrast, our viability assays sample 
the entire well. This increases sampling size and abolishes the need for subjective decisions. In 
addition, the photographer must be blinded to the treatment of the cells for manual counts; a 
requirement that is often not met, as toxin-treated cells typically undergo obvious morphological 
changes such as atrophy or hypertrophy. Our viability assays do not demand that the investigator 
remain blinded. Finally, manual cell counts are a more time consuming process that the relatively 
quick ATP and infrared assays. The incubation period for the ATP assay is approximately fifteen 
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minutes while the scan on the Odyssey Imager for the infrared assays can be as short as five 
minutes. 
On the other hand, the infrared assays also suffer from limitations. The infrared assays 
determine IC50s by measuring 50% loss of signal, not 50% loss of cell numbers per se. If signal 
changes in response to treatment because of hypertrophy or atrophy of the dendritic processes, 
the measurements would not necessarily reflect changes in cell numbers per se, although they 
would still reflect viability. As a result, it is important to immunocytochemically stain the same 
markers as used in the In-Cell Western and examine the cells by microscropy to determine 
structural changes upon toxin treatment.  If the cytoplasm does change with toxin treatment, the 
DRAQ5 stain can be used to quantify nuclei to address this confound. However, the DRAQ5 
signal will also be subject to changes in nuclear size.  
The ATP assay was chosen over other metabolic measures such as the commonly used 
MTT assay due to its higher sensitivity and greater dynamic range. It has been reported that the 
ATP assay can detect a lower limit of 1562 cells per well whereas the MTT assay only has a 
lower limit of 25,000 cells per well (Petty, Sutherland, Hunter, & Cree, 1995). In addition, the 
ATP assay has a higher signal-to-noise ratio than the MTT assay (Riss & Moravec, 2004). 
Finally, the ATP assay is less time consuming and more economical than MTT as it has shorter 
incubation periods and a lower cost. Once again, it is important to bear in mind that metabolic 
activity may not always parallel cell numbers, especially when cells are exposed to low-level 
stress, which can cause a hormetic effect, or during necrosis when there is severe loss of ATP 
output. Therefore, it is critical that ATP measurements are accompanied with the use of a second 
viability assay. 
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In conclusion, the limitations of all assays must be borne in mind, whether high-
throughput or manual, and multiple assays are always superior to a single assay as they generally 
afford a more comprehensive view of cellular integrity provided they are performed within the 
dynamic range of the assay and the instrument. 
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Specific Aim 1b: Create an in vitro model of differential vulnerability of neo- and allocortex and 
examine the underlying mechanisms. Test the hypothesis that neocortex is less vulnerable to 
proteotoxic and oxidative stress than allocortex in vitro. 
Results 
Toxicity of MG132 and Hydrogen Peroxide 
Our next goal was to contrast neo- and allocortical vulnerability to protein misfolding and 
oxidative stress. We hypothesized that neocortex would be more resistant to both types of insults, 
reflecting the topography of neurodegeneration or protein inclusions in Alzheimer’s and 
Parkinson’s disease. First, neo- and allocortical cells were treated with various concentrations of 
the oxidative toxin H2O2 and assayed for MAP2 (Fig. 6A, B) and ATP (Fig. 6C). Allocortex was 
more resistant than neocortex to oxidative stress by both assays. Neo- and allocortex were then 
treated with the proteasome inhibitors MG132 (Fig. 6D-F) and PSI (Fig. 6G-J) to induce 
proteotoxic stress. Neocortex was more resistant than allocortex according to both assays and 
there was a significant statistical interaction between MG132 and brain region by a two-way 
analysis of variance of the MAP2 data (p ≤ 0.05, F=2.411). These data support the view that the 
impact of MG132 on viability depends upon the brain region of origin. As with MG132, the 
difference in vulnerability of neo- and allocortex to proteotoxic stress was only evident at low 
concentrations of PSI (Fig. 6G-I) and not at higher concentrations (Fig. 6J). There was also a 
significant interaction between PSI and brain region, verifying that the topographic origin of the 
cells in culture determined the toxic response to proteasome inhibition (p ≤ 0.001, F=13.99 for 
MAP2, p ≤ 0.001, F=15.07 for ATP). A third proteasome inhibitor was also used, ALLN, which 
elicited a similar response, with neocortex being less vulnerable than allocortex (data not 
shown). Blinded counts of MAP2+ neurons by higher resolution microscopy validated the high-
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throughput In-Cell Western assay, as significant neuronal loss after MG132 treatment was only 
evident in allocortex cultures (Fig. 6K, L). The neuron counts are presented in Figure 6L as the 
raw numbers in order to illustrate the difference in basal survival in neo- and allocortex. In sum, 
these data partially supported our hypothesis, as neocortex is less vulnerable than allocortex to 
proteotoxic stress, but more vulnerable than allocortex to oxidative stress.  
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Figure 6. Differential vulnerability of neo- and allocortex to toxins. A-C: Neo- and allocortical cultures were treated 
with indicated concentrations of hydrogen peroxide. Allocortex was more resistant to oxidative stress by both MAP2 
(A and B) and ATP assays (C). D-F: Neo- and allocortical cultures were treated with indicated concentrations of 
MG132 and assayed for MAP2 (D and E) and ATP (F). Both assays revealed that neocortex was less sensitive to 
low concentrations of this proteasome inhibitor. G-I: Neo- and allocortical cultures were treated with indicated 
concentrations of PSI and assayed for MAP2 (G, H, and J) and ATP (I). Allocortex was more vulnerable to low, 
but not high concentrations of PSI. Shown are the mean and standard error of the mean of at least 3 independent 
experiments. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, or **** p ≤ 0.0001 versus neocortex at the same MG132 
concentration, Bonferroni post hoc correction following two-way ANOVA. K: Representative higher resolution 
photomontage of MAP2 immunostained neocortical and allocortical neurons treated with 0.25 µM MG132 or 
vehicle (dimethyl sulfoxide, DMSO). L: Neurons were counted by a blind observer at 200x magnification in a 0.213 
mm2 field of view (three fields per well). Raw cell counts are shown to illustrate that there were more allocortical 
neurons under basal conditions. However, allocortical neurons were more vulnerable to 0.25 µM MG132. Shown are 
the mean and standard error of the mean of four independent experiments.  ** p ≤ 0.01, **** p ≤ 0.0001 versus 
neocortex; ^^^^ p ≤ 0.0001 MG132 versus vehicle (0 µM MG132); Bonferroni post hoc correction following two-
way ANOVA. Adapted from “Neocortex and Allocortex Respond Differentially to Cellular Stress In Vitro and In 
Vivo,” by J. Posimo, A. Titler, H. Choi, A. Unnithan, and R. Leak 2013, PLoS ONE, 8(3): e58596. 
doi:10.1371/journal.pone.0058596. Copyright 2013 by Posimo et al.  Adapted with permission. 
 
 Interaction between Autophagy and the Ubiquitin-proteasome System 
In Parkinson’s disease and Alzheimer’s disease, the more vulnerable allocortical regions 
are more likely to harbor lipofuscin pigments, lipid residues of failed lysosomal digestion (H. 
Braak et al., 2000; H. Braak, Rüb, et al., 2006). Thus, we hypothesized that autophagic clearance 
of cellular debris would be lower in allocortex than neocortex. Two proteins whose levels reflect 
macroautophagic clearance, Beclin 1 and LC3BII, were not affected by MG132 in neo- or 
allocortex (Fig. 7A, B). However, when the pan-autophagy inhibitor NH4Cl was applied, 
neocortex became as vulnerable as allocortex to 0.25 µM MG132. NH4Cl is a weak base that 
neutralizes lysosomal pH, thereby dramatically inhibiting autophagic protease activity (Fuertes, 
Martin De Llano, Villarroya, Rivett, & Knecht, 2003; Kaushik & Cuervo, 2009; Klionsky, 
Cuervo, & Seglen, 2007). In addition, no further exacerbation of toxicity was observed with 
NH4Cl in allocortex (Fig. 7C). The macroautophagy inhibitor wortmannin was also applied but 
no enhancement of toxicity was observed in either neo- or allocortex (Fig. 7D). Furthermore, the 
macroautophagy enhancer rapamycin was applied in the presence or absence of MG132, but no 
protection against MG132 toxicity was observed (data not shown). These results suggest 
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neocortex may rely on chaperone-mediated or microautophagy to defend against the proteotoxic 
stress caused by MG132 treatment but that allocortex does not rely on any form of autophagy to 
defend against MG132. Repeated attempts were then made to immunostain neo- and allocortical 
cells or to probe by Western blot the chaperone-mediated autophagy marker lysosome-associated 
membrane protein type-2a (LAMP2a), but three antibodies were found to be non-specific in our 
cultures. Moreover, the size of the effect of autophagy inhibition was small, and so we focused 
instead on the role of the ubiquitin-proteasome system in subsequent experiments.  
Ubiquitin is attached to misfolded proteins to target them for proteasomal degradation. 
There was a significant rise in ubiquitin-conjugated protein levels with MG132 treatment in both 
neo- and allocortex. However, allocortex had significantly higher ubiquitin-conjugated protein 
levels than neocortex at both 0.25 µM and 1 µM MG132 (Fig 7E, F). Proteasome activity was 
also measured to gauge the functional integrity of the ubiquitin-proteasome particles. Neo- and 
allocortical cells had significantly reduced chymotrypsin-like proteasome activity following 
treatment with MG132. However, allocortex proteasome activity levels were significantly lower 
than those of neocortex following treatment with 0.25 µM and 1 µM MG132 (Fig. 7G). In sum, 
these data suggest that the ubiquitin-proteasome system for degrading damaged proteins is more 
easily compromised in allocortex than neocortex. 
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Figure 7. Involvement of autophagic defenses and ubiquitin-proteasome system. A-B: Infrared Western 
immunoblotting for macroautophagy-related molecule Beclin 1 following treatment of neo- and allocortical cultures 
with 0.25 and 1 µM MG132 is shown. β-actin was used as a loading control. C-D: Ammonium chloride (20 mM 
NH4Cl) was used to inhibit all forms of autophagy and wortmannin (50 nM) was used to inhibit macroautophagy in 
neo- and allocortical cultures subjected to vehicle or 0.25 µM MG132. Neocortical neurons became as vulnerable to 
MG132 as allocortical neurons in response to NH4Cl. Wortmannin failed to elicit an effect. Shown are the mean and 
standard error of the mean of at least 3 independent experiments. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 allocortex vs 
neocortex; ^ p ≤ 0.05 or ^^^ p ≤ 0.001 MG132 vs vehicle; + p ≤ 0.05 NH4Cl versus vehicle; Bonferroni post hoc 
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correction following two-way ANOVA. E-F: Infrared Western immunoblotting for ubiquitin-conjugated proteins 
revealed that allocortex exhibited higher levels of this measure of proteotoxic stress in response to MG132. G: 
Proteasome activity was measured in the presence or absence of MG132 in a fluorogenic assay. Allocortical 
proteasomes were more inhibited by MG132 than those from neocortex. Shown are the mean and standard error of 
the mean of at least 3 independent experiments. For F and G, * p ≤ 0.05, ** p ≤ 0.01 allocortex versus neocortex; + 
p ≤ 0.05, +++ p ≤ 0.001, ++++ p ≤ 0.0001 MG132 versus vehicle (0 µM MG132); Bonferroni post hoc correction 
following two-way ANOVA. Reprinted from “Neocortex and Allocortex Respond Differentially to Cellular Stress 
In Vitro and In Vivo,” by J. Posimo, A. Titler, H. Choi, A. Unnithan, and R. Leak 2013, PLoS ONE, 8(3): e58596. 
doi:10.1371/journal.pone.0058596. Copyright 2013 by Posimo et al.  Reprinted with permission. 
 
Neo/Allocortical Differences in Stress-sensitive Proteins 
The activated 26S proteasome is formed when PA700 (the 19S regulator) binds to the 
20S proteasome particle. The 20S proteasome particle is activated by the binding of PA28 (the 
11S activator) (Pickering et al., 2010; Voges, Zwickl, & Baumeister, 1999). PA700 interacts 
with the catalytic core in an ATP-dependent manner, thereby providing misfolded proteins 
access to the core particle. The activated 20S proteasome degrades short peptides and non-
ubiquitinated proteins in an ATP-independent manner (Besche, Peth, & Goldberg, 2009; F. 
Shang & Taylor, 2011; Voges et al., 1999). There was no significant difference in basal levels of 
the proteasome activators PA28 and PA700 in neo- and allocortex.  However, allocortex 
expressed significantly higher levels of the proteasome regulators PA28 and PA700 than 
neocortex following MG132 treatment (Fig 8A-C). These findings provide evidence of 
compensatory changes in allocortex in response to proteotoxic stress, perhaps because it is under 
more stress than neocortex. 
Hsp70 refolds denatured proteins or guides irreparably damaged proteins to the 
proteasome or lysosome for degradation (Aridon et al., 2011; Kalia, Kalia, & McLean, 2010; 
Lanneau, Wettstein, Bonniaud, & Garrido, 2010). Hsp70 protects neurons in many experimental 
models of neurodegeneration (Kalia et al., 2010; Sherman & Goldberg, 2001). For example, 
Hsp70 offsets apoptosis and ameliorates MPTP, α-synuclein, and β-amyloid toxicities (Dong, 
Wolfer, Lipp, & Büeler, 2005; Klucken, Shin, Masliah, Hyman, & McLean, 2004; Magrané, 
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Smith, Walsh, & Querfurth, 2004; Moloney et al., 2014; Nagel et al., 2008). Therefore we 
examined Hsp70 levels in neo- and allocortex cultures. Treatment with 1 µM MG132 
significantly increased neo- and allocortical levels of Hsp70 (Fig. 8D, E). When illustrated as a 
fold change (allocortex Hsp70 levels as a function of neocortex Hsp70 levels), allocortex was 
found to express significantly higher levels of Hsp70 than neocortex following treatment with 
0.25 µM MG132 (Fig. 8F).  
Heme oxygenase 1 (HO1; aka Hsp32) is an inducible enzyme essential for heme 
catabolism into carbon monoxide and the antioxidant biliverdin (Aztatzi-Santillán, Nares-López, 
Márquez-Valadez, Aguilera, & Chánez-Cárdenas, 2010; Grochot-Przeczek, Dulak, & Jozkowicz, 
2012; Schipper, Song, Zukor, Hascalovici, & Zeligman, 2009; Wu, Ho, & Yet, 2011). In 
Parkinson’s disease, HO1 expression is increased in astrocytes and can be found in Lewy bodies 
(Schipper, Liberman, & Stopa, 1998). Levels of HO1 were significantly increased in both neo- 
and allocortex with MG132 treatment (Fig. 8G). However, allocortex had significantly higher 
HO1 levels following treatment with 1 µM MG132 than neocortex.  
Catalase is an enzyme that catalyzes the breakdown of H2O2 into water and oxygen. 
Catalase activity is decreased in the hippocampus of aged humans and in the SNpc of 
Parkinson’s patients (Fahn & Cohen, 1992; Venkateshappa, Harish, Mahadevan, Srinivas 
Bharath, & Shankar, 2012). Catalase levels rose significantly in allocortex following MG132 
treatment and were significantly higher in allo- than neocortex following treatment with 0.25 µM 
MG132 (Fig. 8I, J). 
Ceruloplasmin is a copper chaperone and ferroxidase protein that promotes the transport 
of iron out of cells and exhibits antioxidant properties (Hineno et al., 2011; Kaneko et al., 2008; 
Texel et al., 2011). Ceruloplasmin deficient mice are more vulnerable to rotenone and stroke 
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(Brewer et al., 2010; Capo et al., 2008; Kaneko et al., 2008; Kessler et al., 2006; Squitti, 
Quattrocchi, Salustri, & Rossini, 2008; Texel et al., 2011). Furthermore, Parkinson’s patients 
exhibit low ceruloplasmin levels in the cerebrospinal fluid and serum while free copper levels are 
raised (Boll et al., 2008; Torsdottir, Kristinsson, Snaedal, Sveinbjörnsdóttir, et al., 2010). 
Neocortex exhibited significantly higher levels of the ferroxidase ceruloplasmin basally and 
following treatment with 0.25 µM MG132 (Fig. 8K, L). The patterns of higher HO1, Hsp70, and 
catalase expression in allocortex suggest that allocortex has greater need of those defenses in 
response to MG132 toxicity, whereas the basally higher expression of ceruloplasmin in 
neocortex suggests that it might have higher antioxidant defenses and superior iron homeostasis. 
It is also possible that allocortex is more resistant to oxidative stress because of higher catalase 
expression, although further Western blotting studies are needed to confirm this. Furthermore, in 
order to confirm the mechanistic role of these proteins, they must be knocked down with RNA 
interference or inhibited as in Aim 2. 
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Figure 8. Protein changes in neo- and allocortex in response to proteasome inhibition. A-G: Western 
immunoblotting for PA28 (A, B), PA700 10B (B, C), heat shock protein 70 (Hsp70; D, E, F), heme oxygenase 1 
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(HO-1, also known as Hsp32; G, H), catalase (I, J), and ceruloplasmin (K, L) in neocortical and allocortical 
cultures treated with indicated concentrations of MG132. Shown are the mean and standard error of the mean of at 
least 3 independent experiments. * p ≤ 0.05, ** p ≤ 0.01 allocortex versus neocortex; + p ≤ 0.05, ++ p ≤ 0.01, +++ p 
≤ 0.001, ++++ p ≤ 0.0001 MG132 versus vehicle; Bonferroni post hoc correction following one or two-way 
ANOVA. Reprinted from “Neocortex and Allocortex Respond Differentially to Cellular Stress In Vitro and In 
Vivo,” by J. Posimo, A. Titler, H. Choi, A. Unnithan, and R. Leak 2013, PLoS ONE, 8(3): e58596. 
doi:10.1371/journal.pone.0058596. Copyright 2013 by Posimo et al.  Reprinted with permission. 
 
Involvement of Glutathione in Defense Against Proteotoxicity 
Loss of the ubiquitous tripeptide antioxidant glutathione is one of the earliest pathologies 
in Parkinson’s disease (Martin & Teismann, 2009; Sian, Dexter, Lees, Daniel, Agid, et al., 1994; 
Sofic et al., 1992; Zeevalk et al., 2008). Thus, we measured glutathione levels in neo- and 
allocortex in the absence and presence of MG132 exposure. Glutathione levels were significantly 
higher in neocortex than allocortex, both basally and following 0.25 µM MG132 treatment (Fig. 
9A). In order to determine the role of glutathione in the differential vulnerability of neo- and 
allocortex to MG132-induced proteotoxicity, glutathione levels were decreased with the 
glutamate cysteine ligase inhibitor buthionine sulfoximine (BSO). MAP2 and glutathione levels 
were measured in neo- and allocortex after treatment with BSO. BSO was not toxic until 
concentrations of 50 µM were reached (data not shown). Significant decreases in glutathione 
were apparent in neocortex with concentrations as low as 3.125 µM BSO (Fig. 9B, C). No 
significant decrease in glutathione levels was observed in allocortex in response to BSO. 
Nonetheless, MG132-induced cell loss was exacerbated by BSO in neurons from both regions 
(Fig. 9D, E). These findings suggest that endogenous antioxidant defenses from glutathione help 
mitigate proteotoxicity in neocortex. 
The thiol N-acetyl cysteine has been shown to improve cognitive function in Alzheimer’s 
disease (Adair, Knoefel, & Morgan, 2001) and is currently undergoing clinical trials in 
Parkinson’s patients (ClinicalTrials.gov Identifier: NCT02212678). N-acetyl cysteine has also 
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been shown to increase brain and blood glutathione levels in Parkinson’s patients (Holmay et al., 
2013). Therefore, we tested the hypothesis that N-acetyl cysteine would protect allocortical cells 
by raising glutathione levels. As expected, treatment with N-acetyl cysteine protected allocortex 
from MG132 toxicity, rendering it as resilient as neocortex (Fig. 9F, G).  These results support 
the use of N-acetyl cysteine in neurological conditions that affect the allocortex of the 
telencephalon. 
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Figure 9. Role of glutathione in protection of neo- and allocortex against proteasome inhibition. A: Glutathione 
(GSH) levels as a function of total MAP2 levels in neocortex and allocortex in the presence or absence of MG132. 
Allocortical cells exhibited less glutathione than neocortical cells in both conditions in vitro. B-C: MAP2 levels (B) 
and glutathione levels (C) as a function of indicated concentrations of buthionine sulfoximine (BSO). Neocortical 
cells exhibited much greater glutathione loss with buthionine sulfoximine than allocortical cells. Buthionine 
sulfoximine was not lethal to neurons at the indicated concentrations. D-E: Neocortical and allocortical neurons 
were treated with vehicle or MG132 (0.25 µM) and vehicle or buthionine sulfoximine (12.5 µM). Both allocortical 
neurons and neocortical neurons were more vulnerable to combined treatment with buthionine sulfoximine and 
MG132 than either toxin alone (D). The glutathione assay revealed again that neocortical cells lost more glutathione 
with buthionine sulfoximine than allocortical cells, but that allocortical cells had overall less glutathione than 
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neocortical cells in all four groups (E). F-G: N-acetyl cysteine (3 mM) completely prevented the toxicity of 0.25 µM 
MG132 in allocortical cultures (F) and considerably raised glutathione levels both with and without MG132 on 
board (G). Shown are the mean and standard error of the mean of at least 3 independent experiments. For all panels, 
* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, or **** p ≤ 0.0001  allocortex versus neocortex; ^ p ≤ 0.05, ^^ p ≤ 0.01, ^^^ 
p ≤ 0.001, or ^^^^ p ≤ 0.0001 MG132 versus vehicle; + p ≤ 0.05, ++ p ≤ 0.01, +++ p ≤ 0.001, ++++ p ≤ 0.0001 
buthionine sulfoximine versus water or N-acetyl cysteine versus water; Bonferroni post hoc correction following 
two-way ANOVA. Reprinted from “Neocortex and Allocortex Respond Differentially to Cellular Stress In Vitro and 
In Vivo,” by J. Posimo, A. Titler, H. Choi, A. Unnithan, and R. Leak 2013, PLoS ONE, 8(3): e58596. 
doi:10.1371/journal.pone.0058596. Copyright 2013 by Posimo et al.  Reprinted with permission. 
 
Discussion 
 The present study is the first to report that the neo- and allocortex are differentially 
vulnerable to low levels of proteotoxicity, consistent with the staged appearance of protein 
aggregations in the cortical edifice in Parkinson’s disease (H. Braak, Del Tredici, Rüb, et al., 
2003; H. Braak, Rüb, et al., 2006; Stranahan & Mattson, 2010). Although neocortex was more 
resistant to proteotoxic stress, it was more vulnerable to oxidative stress than allocortex, as 
shown following exposure to two oxidative toxins: paraquat and H2O2. This unexpected finding 
was consistent with the higher survival rates of allocortex in BME/BCS media, as cell culture 
procedures are thought to elicit high basal levels of oxidative stress on their own (Halliwell, 
2014). Neurobasal media with B27 supplementation may offer superior antioxidant support, 
leading to significant improvements in neuronal survival (C. Xie, Markesbery, & Lovell, 2000). 
The discrepancy between the responses to proteasome inhibitors and oxidative toxins was 
unexpected because 1) oxidative and proteotoxic stress typically work in synergistic manners and 
2) allocortical cultures exhibited lower levels of two antioxidants, ceruloplasmin and glutathione, 
than neocortical cultures. On the other hand, the allocortex is known to exhibit less myelination 
than neocortex and therefore may be subjected to higher metabolic demands and higher levels of 
oxidative stress in vivo (H. Braak, Rüb, Gai, & Del Tredici, 2003). In response to poor 
myelination and higher free radical levels, allocortex may have evolved greater defenses against 
oxidative injuries. Alternatively, postnatal allocortex cultures from rat pups may not reflect the 
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selective vulnerabilities that are evident in vivo in humans, especially in aged human subjects. It 
is worth noting that Braak’s staging scheme is not based on measures of oxidative stress per se 
but on immunohistochemical staining for misfolded α-synuclein, an established sign of 
proteotoxic stress. Furthermore, the frontal neocortex does exhibit high levels of oxidative stress 
in incidental Lewy body disease (Dalfó et al., 2005), suggesting that our H2O2 results may indeed 
reflect conditions in the diseased human brain. It is also possible that neocortical vulnerability to 
oxidative stress reflects the earlier amyloid deposition in this structure in Alzheimer’s disease (H. 
Braak & Braak, 1991), although amyloid deposition does not correlate with cell loss or with 
clinical symptoms (Arriagada et al., 1992; Bierer et al., 1995; Giannakopoulos et al., 2003). In 
contrast to the findings with oxidative toxins, neocortex was more resilient than allocortex 
following exposure to the proteasome inhibitors MG132 and PSI, as shown by two independent 
viability assays and as confirmed by manual counts of MAP2+ neuronal elements. These results 
indicate that proteasome inhibitors are more appropriate than oxidative toxins for modeling the 
topography of α-synuclein and tau inclusions in Parkinson’s and Alzheimer’s disease. As with 
any cell culture model, one important limitation is that cell death is acute in vitro compared to 
the extended neurodegenerative process that unfolds over decades in patients. MG132 and H2O2 
are nevertheless relevant to Parkinson’s disease because inhibition of the ubiquitin-proteasome 
system and indices of oxidative stress are evident in the disorder (Alam et al., 1997; D. Dexter et 
al., 1986; Floor & Wetzel, 1998; Jenner, 1998; McNaught et al., 2003; McNaught, Belizaire, 
Jenner, Olanow, & Isacson, 2002; McNaught & Jenner, 2001; Sian, Dexter, Lees, Daniel, Agid, 
et al., 1994).  
The two major intracellular protein degradation systems, the ubiquitin proteasome system 
and autophagy, are both highly neuroprotective and prevent loss of protein homeostasis 
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(Nedelsky, Todd, & Taylor, 2008). Thus, both of these systems were investigated in our primary 
culture model to assess the role they may play in the differential vulnerability of neo- and 
allocortex to proteotoxic stress. The macroautophagy inhibitor, wortmannin, exerted no impact 
on neo- and allocortical vulnerability to MG132, suggesting that neurons from either region do 
not rely on macroautophagy for protection against MG132. Additionally, raising 
macroautophagy defenses with rapamycin failed to protect allocortex against MG132. NH4Cl, a 
pan autophagy inhibitor, had no impact on MG132 toxicity in allocortex. Thus, we conclude that 
allocortex does not rely on autophagy to battle MG132-associated proteotoxicity in vitro. In 
contrast, when neocortex was treated with NH4Cl, MG132 toxicity was significantly 
exacerbated. Therefore, neocortical cells may rely on chaperone-mediated or microautophagy for 
protection against proteasome inhibition. These differences in autophagic defenses in neo- and 
allocortex are consistent with previous observations that lipofuscin granules–evidence of 
autophagy failure–are more prevalent in regions with denser protein inclusions (H. Braak et al., 
2000; H. Braak, Rüb, et al., 2006). Efforts to differentiate between these different types of 
autophagy were abandoned due to a lack of specificity of three different LAMP2a antibodies and 
the small effect size following NH4Cl treatment. Thus, we focused our efforts on the role of the 
ubiquitin proteasome system instead.    
 Consistent with Braak staging schemes, allocortex was subjected to greater proteotoxic 
stress than neocortex according to the viability assays, proteasome activity data, and ubiquitin-
conjugated protein levels. As expected, allocortical proteasome activity levels were even lower 
than neocortical levels following MG132 treatment. In addition, ubiquitin-conjugated protein 
levels rose significantly higher following MG132 treatment, especially in allocortex, suggesting 
that MG132 was effective in reducing misfolded protein clearance in both regions. Allocortex 
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also exhibited higher levels of the proteasome activators PA700 and PA28 than neocortex. This 
may seem unexpected because allocortex exhibited higher levels of ubiquitin-conjugated proteins 
than neocortex and therefore might be hypothesized to have fewer proteasome particles. 
However, the results are consistent with previous studies showing that proteasome subunit levels 
are increased in the presence of elevated ubiquitin-conjugated proteins (Bazzaro et al., 2006). 
Thus, we speculate that higher levels of proteotoxic stress in allocortex elicit a greater 
compensatory response in proteasome subunit expression than in neocortex.  
Consistent with greater proteasome subunit levels in allocortex, allocortex also expressed 
higher levels of the heat shock chaperone Hsp70 and the antioxidant catalase than neocortex 
following treatment with 0.25 µM MG132. Thus, the rise in stress-sensitive proteins in 
allocortex may reflect higher levels of proteotoxic stress than in neocortex. Furthermore, without 
this defensive response, allocortex would probably have been even more vulnerable to MG132 
toxicity. However, it must be conceded that our Western blotting data are only correlative. In 
order to determine if the upregulation of stress-sensitive proteins in allocortex confer protection 
against proteotoxicity, knockdown or inhibition studies must be performed. Furthermore, mRNA 
studies would be required to determine whether protein synthesis is enhanced or protein 
clearance is inhibited, as both responses would result in increases in protein levels by Western 
blot analyses. Nevertheless, the observed rise in stress-sensitive proteins in allocortex is 
consistent with the hypothesis that the levels of these proteins are in proportion to the degree of 
proteotoxic stress.  
 Glutathione is one of the most abundant and ubiquitous antioxidants, being present in 
millimolar concentrations in most tissues. The involvement of glutathione was investigated in the 
present study because proteotoxic and oxidative stress are often synergistic (Dringen, 2000; 
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Pompella, Visvikis, Paolicchi, De Tata, & Casini, 2003). The glutathione synthesis inhibitor 
BSO was more effective in neocortex than allocortex, perhaps because allocortex already had 
extremely low levels of glutathione synthesis under baseline conditions. Nonetheless, MG132 
toxicity was exacerbated in neurons from both regions in the presence of BSO, suggesting that 
perhaps both types of neurons use glutathione in self-defense against proteotoxicity. As 
expected, N-acetyl cysteine increased glutathione levels in allocortex and protected it against 
MG132 toxicity. Limitations of these studies include recognition of both reduced and oxidized 
glutathione by the glutathione antibody. However, the vast majority of cellular glutathione is 
kept in the reduced state, even in injured conditions (Pastore, Federici, Bertini, & Piemonte, 
2003; Shen, Dalton, Nebert, & Shertzer, 2005). A second limitation is that the difference in 
glutathione levels between neo- and allocortex may only be evident during postnatal 
development or be attributable to the harvesting and culturing procedures.  
 The ferroxidase ceruloplasmin did not rise with MG132 treatment in vitro. Thus, the 
higher levels of ceruloplasmin in neocortex under baseline conditions and with 0.25 µM MG132 
are not likely to reflect greater stress levels. Many studies have linked ceruloplasmin to 
Parkinson’s disease. As mentioned earlier, lower serum levels of ceruloplasmin have been 
correlated with a younger disease onset (Bharucha et al., 2008). In addition, loss of function 
mutations in ceruloplasmin lead to extrapyramidal symptoms and parkinsonism associated with 
iron toxicity (Hochstrasser et al., 2004; Hochstrasser et al., 2005; Jin et al., 2011; Lirong et al., 
2009; H. F. Shang, Jiang, Burgunder, Chen, & Zhou, 2006). Ceruloplasmin immunostaining is 
higher in the remaining neurons of the SNpc in Parkinson’s disease compared to healthy control 
subjects (Loeffler et al., 1996). Therefore, higher levels of ceruloplasmin in neocortical neurons 
may at least partly explain neocortical resilience against Parkinson’s pathology. 
 60 
Specific Aim 1c: Determine the differential susceptibility of neocortex and three allocortical 
subregions (entorhinal cortex, hippocampus, and olfactory bulb) to α-synuclein fibril-induced 
proteotoxic stress. Test the hypothesis that brain region of origin dictates the extent of Lewy-like 
inclusion formation and cell death in vitro. 
Results  
Inclusion formation in hippocampal and olfactory bulb primary cultures 
Aggregated α-synuclein fibrils can elicit Parkinson’s pathology in a number of cellular 
and animal models (Luk, Kehm, Carroll, et al., 2012; Luk, Kehm, Zhang, et al., 2012; Luk et al., 
2009; Recasens et al., 2014; Sacino, Brooks, McKinney, et al., 2014; Sacino, Brooks, Thomas, et 
al., 2014; Volpicelli-Daley, Luk, & Lee, 2014a; Volpicelli-Daley et al., 2011a). As stated above, 
Lewy pathology forms across widespread brain regions in Parkinson’s disease and is not 
restricted to the ventral mesencephalon as previously hypothesized (H. Braak, Del Tredici, 
Bratzke, Hamm-Clement, Sandmann-Keil, & Rub, 2002; H. Braak, Del Tredici, Rub, et al., 
2003; H. Braak, Rub, et al., 2006). For example, cortical Lewy pathology spreads extensively 
throughout the allocortex following the appearance of inclusions in the entorhinal area. Thus, we 
sought to elicit Lewy-like inclusions and cell loss in primary cultures of the neocortex and three 
subregions of the allocortex–the hippocampus, the olfactory bulb, and the entorhinal area–using 
preformed α-synuclein fibrils kindly donated by Kelvin Luk and Virginia Lee from the 
University of Pennsylvania (Note: In the Figures, if not specified, the label ‘allocortex’ refers to 
the entorhinal area). First we observed that hippocampal and olfactory bulb primary neurons 
form inclusions positive for the aggregated form of α-synuclein (phosphorylated at serine 129 or 
pSer129) within 7 days of treatment with α-synuclein fibrils (Fig. 10A). The inclusions were 
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found within the cellular processes and the soma, where the aggregated protein appeared to be 
wrapped around the nucleus (Fig. 10B merged).  
                     
Figure 10: α-synuclein fibrils elicit the formation of neuronal inclusions. Hippocampal and olfactory bulb cultures 
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were treated with α-synuclein fibrils on DIV2 and fixed one week later. (A) Cells were immunocytochemically 
stained for the aggregated form of α-synuclein, which is phosphorylated at serine 129 (pSer129). Nuclei were stained 
with Hoechst. (B) Higher magnification images of olfactory bulb cultures immunostained for pSer129 and the 
specific neuronal marker β-tubulin III. White arrows denote some of the Lewy-like α-synuclein+ inclusions that 
colocalize with β-tubulin III. 
 
pSer129+ inclusions are insoluble in Triton-X 100 
 In the human disease, Lewy bodies and Lewy neurites have precipitated out of solution 
and remain insoluble even in the presence of mild detergents in postmortem tissue (Galloway, 
Mulvihill, & Perry, 1992). Thus, we treated hippocampal neurons with α-synuclein fibrils and 
then fixed with 4% paraformaldehyde in the presence or absence of 1% Triton X-100 one week 
later to determine if our inclusions are indeed insoluble. In agreement Luk and colleagues, the 
pSer129+ inclusions in our hippocampal cultures were insoluble in Triton X detergent as 
expected (Fig. 11) (Volpicelli-Daley et al., 2011a). Thus, treatment with α-synuclein fibrils in 
vitro recapitulates the insolubility of the inclusions that develop in Parkinson’s disease.  
 
Figure 11: α-synuclein inclusion formations are insoluble in detergent. Hippocampal neurons were treated on DIV2 
with α-synuclein fibrils and fixed with 4% paraformaldehyde in the presence or absence of 1% Triton X-100 one 
week later. Cells were then immunocytochemically stained for α-synuclein phosphorylated at serine 129. Nuclei 
were stained with Hoechst.  
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α-synuclein fibrils increase the number of Thioflavin S+ amyloid structures 
 In Parkinson’s and Alzheimer’s disease, proteins that precipitate out of solution after 
acquiring beta-sheet pleated structures are commonly identified by the Thioflavin S stain as 
amyloid in nature (Westermark, Johnson, & Westermark, 1999). In addition to determining the 
insolubility of the inclusions formed by α-synuclein fibril treatment, we used Thioflavin S 
staining to assess the presence of amyloid structures. As hippocampal neurons formed the most 
inclusions when treated with α-synuclein fibrils, this hypothesis was tested in hippocampal 
cultures. In the absence of fibrils, Thioflavin S staining was absent (Fig. 12Aa-c). Treatment with 
α-synuclein fibrils dramatically enhanced staining for Thioflavin S (Fig. 12Ad-i, B). Thus, α-
synuclein fibril treatment increases amyloid structures in hippocampal neurons as expected.  
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Figure 12: α-synuclein fibrils elicit Thioflavin S+ amyloid formations. Hippocampal cultures were treated with α-
synuclein fibrils on DIV2 and fixed one week later. (A) Amyloid structures with β-pleated sheets were stained with 
Thioflavin S (green). Nuclei were stained with Hoechst (blue). (Ag-i) Higher magnification images correspond to 
the white insets in panel d. (B) Thioflavin S staining was quantified in Image J by a blinded observer and expressed 
as a fraction of Hoechst+ cell numbers. Shown are the mean and SEM of 3 independent experiments, each performed 
in triplicate. ** p ≤ 0.01 versus 0 µg/mL α-synuclein fibrils. 
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α-synuclein fibril treatment does not elicit cell loss 
 Next we treated primary cultures from neocortex and three subregions of allocortex in 
parallel with synuclein fibrils to test the hypothesis that cellular viability would be reduced. 
Primary neocortical, entorhinal, hippocampal, and olfactory bulb cultures were treated with α-
synuclein fibrils for one week but no significant decrease in cellular viability was observed by 
the DRAQ5 and MAP2 assays (Fig. 13A-D). In agreement with the infrared assays, no loss in 
viability was elicited with α-synuclein fibril treatment according to blinded counts of Hoechst+ 
cell numbers (Fig. 13E, F). Furthermore, there were no significant changes in average nuclear 
size, also a sign of cellular stress (Fig. 13G, H). The size of Hoechst+ nuclei in neocortex cultures 
was smaller than in the hippocampus following α-synuclein fibril treatment, although the 
difference was minor (Fig. 13H). Instead of eliciting cellular loss, α-synuclein fibril treatment 
slightly increased signal in the nuclear DRAQ5 assay in neocortical cultures. A similar pattern 
was observed in the numbers of Hoechst+ cells (Fig. 13B, F), suggestive of a mild hormetic 
effect. Also consistent with a hormetic effect, MAP2 levels were significantly increased in 
hippocampal cultures treated with α-synuclein fibrils (Fig. 13D). This effect was further 
investigated in subsequent studies.  
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Figure 13: Impact of α-synuclein fibril treatment in neo- and allocortical neurons. Neocortical neurons and neurons 
from three allocortical subregions−entorhinal cortex, hippocampus, and olfactory bulb-were treated with vehicle or 4 
µg/mL α-synuclein fibrils on DIV2. Three viability assays were performed on DIV9. (A-F) Nuclei were stained with 
DRAQ5 or Hoechst and neurons were stained for MAP2 using the In-Cell Western technique. Raw and normalized 
data are both presented. The normalized data in B, D, F, and H are presented as fold change from the corresponding 
vehicle-treated group. (B, F) α-synuclein treatment increased DRAQ5 signal and Hoechst+ cells in neocortical 
cultures. (G, H) There was no significant difference in average nuclear size, with the exception that α-synuclein 
treated neocortical cultures exhibited slightly smaller nuclei than hippocampal cultures. (D) MAP2 levels were 
significantly higher in hippocampal cultures treated with α-synuclein fibrils. Shown are the mean and SEM of 3-6 
independent experiments, each performed in duplicate or triplicate. * p ≤ 0.05, ** p ≤ 0.01 versus 0 µg/mL α-
synuclein fibrils.  ^ p ≤ 0.05 versus hippocampus. ~ p ≤ 0.05, ~~ p ≤ 0.01  versus olfactory bulb, two-way ANOVA 
followed by Bonferroni post hoc correction. 
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α-synuclein fibril treatment elicits an increase in MAP2 levels in hippocampal neurons  
As previously discussed, MAP2 levels were significantly increased in α-synuclein fibril 
treated hippocampal neurons as assessed by an infrared In-Cell Western assay on the LICOR 
Odyssey Imager (Fig. 13D). However, immunocytochemical analyses revealed that α-synuclein 
fibril treatment did not affect the number and cell density of MAP2+ neurons (Fig. 14A, B). 
MAP2+ area fraction–the fraction of the field of view with MAP2+ immunoreactivity–was also 
analyzed but showed no increase with α-synuclein fibril treatment (Fig. 14C).  It is possible that 
some dendritic processes are too lightly stained to be recognized by an EVOS epifluorescence 
microscope, whereas the infrared Odyssey imager can visualize this difference due to much 
higher sensitivity.  
In order to verify the increase in MAP2 in fibril-treated hippocampal neurons, Western 
blotting was performed. α-synuclein fibril treatment significantly increased MAP2, GAPDH, and 
β-actin levels as if there was on overall increase in protein content (Fig. 14F-H). When MAP2 
levels were expressed as a function of GAPDH levels, there was no change in MAP2 
concentration (Fig. 14D). However, when we plotted protein concentration as determined by the   
bicinchoninic assay, a significant decrease in protein levels with α-synuclein fibril treatment 
became evident (Fig. 14E). It is possible that the bicinchoninic assay does not work well under 
conditions of protein aggregation as in the fibril-treated groups and that the fibrils elicit a small 
increase in dendritic arbors without a concomitant change in cell numbers. Indeed, MAP2 is 
commonly used as a dendritic marker (Bernhardt & Matus, 1984). These findings raise the 
possibility that neurons respond to the presence of inclusions in their processes by upregulating 
dendritic outgrowth to compensate for the blockade of retrograde and anterograde transport 
systems. Future studies to investigate this possibility are warranted. 
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Figure 14: Effect of α-synuclein fibrils on hippocampal MAP2 levels. (A-C) α-synuclein fibrils had no effect on the 
number, density, or area fraction of MAP2+ hippocampal neurons as assessed by an EVOS epifluorescence 
microscope. Representative images of MAP2 and Hoechst-stained cells after treatment with α-synuclein fibrils. (D) 
There was no significant change in MAP2 levels as a function of GAPDH levels in hippocampal neurons. (E) Total 
protein levels were significantly decreased in α-synuclein fibril treated hippocampal neurons as assessed by the 
bicinchoninic assay. (F-H) Levels of MAP2, GAPDH, and β-actin were increased in α-synuclein fibril-treated 
hippocampal neurons according to Western immunoblots. Shown are the mean and SEM of 3-5 independent 
experiments, each performed in triplicate. * p ≤ 0.05, ** p ≤ 0.01 versus 0 µg/mL α-synuclein fibrils, two-tailed 
Student t test.  
 
 
A
B
C
GAPDH `ͲĂĐƟŶ
D
MAP2
Fibrils	  (+g/mL):
E
F
_
ͲƐǇ
ŶƵ
ĐůĞ
ŝŶ
Į
ďƌ
ŝůƐ
;+
g/
m
L)
:
0
4
MAP2,ŽĞĐŚƐƚ
Fibrils	  (+g/mL): Fibrils	  (+g/mL):
G H
 69 
Brain region of origin determines vulnerability to inclusion formation in vitro 
Our next goal was to establish whether neocortical cultures developed fewer inclusions 
than allocortical cultures. As expected, pSer129+ inclusion formation occurred in all primary 
neuronal cultures treated with α-synuclein fibrils (Fig. 15A-E). Hippocampal neurons had the 
highest inclusion numbers whereas olfactory bulb and neocortical cultures had the lowest (Fig. 
15A, D). Inclusion numbers were assessed as a function of both DRAQ5 and Hoechst+ cell 
numbers as each method exhibits unique strengths and weaknesses, as discussed in Specific Aim 
1a. Inclusion area fraction was highest in hippocampal cultures and lowest in olfactory bulb 
cultures, consistent with the inclusion number results (Fig. 15C, E). Neocortical neurons had the 
largest average inclusion size compared to the other neuronal cultures (Fig. 15F).  These patterns 
are highly suggestive of selective susceptibility to α-synuclein pathology, with the highest 
susceptibility in hippocampal neurons. One potential explanation for these results is the 
differential expression of endogenous α-synuclein; if α-synuclein levels are naturally low in a 
given brain region, there would be less available for inclusion formation. Consistent with this 
view, Western blotting analysis revealed that hippocampal neurons expressed the highest levels 
of α-synuclein of all the brain regions examined (Fig. 15G). 
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Figure 15: Impact of α-synuclein fibril treatment on neuronal and nuclear markers. (A, C) The number of pSer129+ 
inclusion counts and the fraction of the total surface area that was occupied by inclusions were expressed as a 
function of Hoechst+ cell numbers. Hippocampal neurons exhibited the highest levels of inclusion formation. (B) 
Representative Hoechst and pSer129 images from each brain region examined. (D, E) The same measurements as in 
A and C were expressed as a function of the nuclear stain DRAQ5. (F) The average size of the pSer129+ inclusions 
was significantly higher in neocortical cultures than in entorhinal cortical and hippocampal cultures. (G) Basal 
levels of α-synuclein expression in neurons from each brain region. Shown are the mean and SEM of 5-6 
independent experiments, each performed in triplicate * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 versus 0 µg/mL α-
synuclein fibrils. ^ p ≤ 0.05, ^^ p ≤ 0.01, ^^^ p ≤ 0.001 versus hippocampus. ## p ≤ 0.01 versus neocortex. ~ p ≤ 
0.05 versus olfactory bulb, one or two-way ANOVA followed by Bonferroni post hoc correction. 
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Discussion 
The goal of Specific Aim 1c was to assess the effects of α-synuclein fibril treatment in 
primary neuronal cultures harvested from multiple brain regions. We tested the hypothesis that 
neocortex would be the least susceptible to synucleinopathy and cell loss and that brain region of 
origin would play an important role in determining susceptibility to inclusion formation. We 
gathered partial support for our hypotheses, as brain region did determine the extent of inclusion 
formation, but the Lewy-like inclusions did not elicit cell loss in vitro as previously reported 
(Luk et al., 2009; Volpicelli-Daley et al., 2014a; Volpicelli-Daley et al., 2011b). This 
discrepancy may be attributed to differences in the duration of treatment; our cultures were 
assayed after one week whereas previous studies reported effects after two weeks. Other 
significant differences include the type of sonicator and probe used (Kelvin Luk, personal 
communication). Nevertheless, α-synuclein fibril treatment successfully elicited inclusion 
formation in all four primary culture types. The inclusions formed in our hands exhibited Lewy-
like characteristics, as they were detergent-insoluble and found most abundantly throughout 
cellular processes.  
As mentioned above, we observed that the degree of inclusion formation was heavily 
dependent on the brain region of origin. This is consistent with the view that not all brain regions 
are equally susceptible to synucleinopathy. However, the degree of susceptibility to α-synuclein 
fibril-induced inclusion formation did not correlate with the observed progression of pathology 
in the disease, with the exception that hippocampus was more vulnerable than neocortex (H. 
Braak, Del Tredici, Rüb, et al., 2003). According to Braak’s staging scheme, the most 
susceptible regions in our studies should have been the olfactory bulb, hippocampus, entorhinal 
cortex, and neocortex, in descending order. In contrast, we observed that olfactory bulb and 
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neocortical neurons developed the least inclusions whereas hippocampal neurons developed the 
most. As mentioned in the Introduction, the selective susceptibility of different brain regions in 
Parkinson’s disease is superimposed upon the efferent and afferent projection patterns. 
Obviously, the latter determine whether or not neurons have access to misfolded α-synuclein 
according to Braak’s transmissibility hypothesis. Nevertheless, one of the strengths of our model 
is that removal of the inter-neuronal connections between brain regions by mechanical 
dissociation led to the discovery of inherent selective susceptibilities to synucleinopathy. 
α-synuclein fibril-treated olfactory bulb and neocortical neurons developed the least 
number of inclusions in vitro. This is consistent with the observation that the neocortex is the last 
region affected by α-synuclein pathology (H. Braak, Del Tredici, Rüb, et al., 2003). However, 
olfactory structures are affected by α-synuclein pathology very early in the disease, leading us to 
expect that this region would have been especially vulnerable to inclusion formation (H. Braak, 
Del Tredici, Rüb, et al., 2003). Our results are consistent with the view that olfactory regions are 
not inherently vulnerable to protein misfolding stress but that they develop inclusions early in 
Parkinson’s disease perhaps because they lie in close proximity to the route of entry of a 
pathogenic insult. Nasal and vagal routes of entry of a pathogen in Parkinson’s disease have been 
proposed by several investigators in recent years (H. Braak, Rüb, et al., 2003; Rey, Petit, 
Bousset, Melki, & Brundin, 2013). 
Consistent with Braak staging theory, entorhinal neurons developed inclusions more 
readily then neocortical neurons when only these two brain regions were statistically analyzed. 
This finding is in agreement with previous data from Specific Aim 1b, which showed that 
neocortex was more resistant to the proteasome inhibitors MG132 and PSI than allocortex. 
Together these studies suggest that entorhinal neurons are more susceptible to proteotoxicity and 
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consequently, inclusion formation, than neocortical neurons. Notably, hippocampal neurons 
developed the most extensive inclusion formation although they do not develop Lewy pathology 
until stage 3 of the disease, well after olfactory Lewy bodies make an appearance (Lerner & 
Bagic, 2008). The reason for the enhanced susceptibility of hippocampal neurons may be higher 
basal expression of endogenous α-synuclein compared to neurons from the entorhinal cortex, 
neocortex, and olfactory bulb. Higher levels of α-synuclein might provide a greater pool of 
potential substrates for α-synuclein fibrils to seed protein misfolding.  
In conclusion, neurons exhibit selective susceptibility to synucleinopathy as expected. 
These findings underscore the importance of brain region both when testing potential therapies 
and choosing a model system to study. 
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Chapter 2  
Specific Aim 2: Examine whether neo- and allocortical cells differ in their reliance on heat shock 
proteins for defense against protein misfolding stress. Test the hypothesis that neocortex is less 
vulnerable than allocortex to loss of protein homeostasis from simultaneous inhibition of heat 
shock protein and proteasome activity. If supported, this would suggest that the stressed 
allocortex is more vulnerable to loss of heat shock protein activity because it needs to rely on 
these defenses more when challenged with protein misfolding stress. Furthermore, these findings 
would lend insight into the mechanisms underlying selective vulnerability patterns in 
telencephalic subregions. 
Rationale 
 Heat shock proteins and the ubiquitin-proteasome system are primary cellular defenses 
against proteotoxic stress. Heat shock proteins are chaperones that refold misfolded proteins and 
form part of the essential vitagene network that preserves homeostasis in the brain (Cornelius, 
Perrotta, Graziano, Calabrese, & Calabrese, 2013). Misfolded proteins are tagged with ubiquitin 
and guided to the proteasome by heat shock proteins if they are irreparably damaged and cannot 
be refolded. Following proteasome inhibition, misfolded proteins are no longer degraded and 
promote the formation of protein aggregates and cell death (Rideout, Larsen, Sulzer, & Stefanis, 
2001; Rideout & Stefanis, 2002; Sun et al., 2006). However, the role of heat shock proteins in 
regionally selective vulnerability to proteotoxicity in the telencephalon has not been defined.   
Results 
Optimization of Primary Culture Model 
Earlier work revealed that neocortical neurons did not survive the culturing process as 
well as entorhinal allocortical neurons. As a result of this baseline toxicity of the culturing 
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conditions, we switched to Neurobasal-A medium, which is specifically designed to promote the 
survival of postnatal neurons. In this new medium, neo- and allocortical neurons survived 
culturing conditions equally well and densely expressed the synaptic marker synaptophysin (Fig 
16A, B). There was no difference in the overall number of MAP2+ cells in neo- versus 
allocortical cultures (Fig 16C). However, allocortical cultures exhibited lower neuronal densities 
(fewer MAP2+ cells as a fraction of Hoechst+ cell numbers) than neocortical cultures, although 
the difference was very slight (<10%) (Fig. 16D). No differences were observed between neo- 
and allocortical cultures in MAP2 or ATP levels as assessed by the In-Cell Western and Cell 
Titer Glo assays, respectively (Fig. 16E, F). For all subsequent experiments, we therefore used 
Neurobasal-A media. 
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Figure 16: Primary postnatal cultures of neo- and allocortex. (A, B) Primary sensorimotor neocortex and entorhinal 
allocortex cells were harvested from 1 or 2 day-old rat pups and stained for the neuronal marker MAP2, the synaptic 
marker synaptophysin, and the nuclear stain Hoechst on DIV4. (C, D) MAP2+ neurons and Hoechst-stained nuclei 
were counted by a blinded observer to assess the neuronal density and purity of the cultures. Neocortex had slightly 
higher levels of MAP2+ neurons as a percentage of total cell numbers. (E, F) No difference in overall MAP2 content 
or ATP levels was observed between neo- and allocortical cultures on DIV4, according to the In-Cell Western assay 
for MAP2 and the Cell Titer Glo assay for ATP. A representative In-Cell Western image is shown above panel E. 
Shown are the mean ± SEM of at least 3 independent experiments. ** p ≤ 0.01 vs neocortex, two-tailed Student’s t-
test. Reprinted from Neurobiology of Aging, 36 (5), J. Posimo, J. Weilnau, A. Gleixner, M. Broeren, N. Weiland, J. 
Brodsky, P. Wipf, and R. Leak, “Heat shock protein defenses in the neocortex and allocortex of the telencephalon,” 
p. 1924-1937. Copyright 2015 by Elsevier, reprinted with permission from Elsevier. 
 
 
Regional Differences in Vulnerability to Cellular Stress 
After reestablishing our culture model with improvements in neuronal density and basal 
survival, we examined the stress vulnerability of cells harvested from neocortex and three 
allocortical subregions (entorhinal allocortex, piriform cortex, and hippocampus). As observed 
previously, neocortex was more resistant to MG132 toxicity than entorhinal allocortex according 
to the MAP2 and ATP assays (Fig 17A, B). At the highest concentration of MG132, entorhinal 
allocortical neurons exhibited higher levels of ATP, which may be attributed to glial cells 
because this difference is absent in the MAP2 assay. Additionally, neocortex cultures were more 
resistant to MG132 compared to piriform cortex and hippocampus cultures according to the 
MAP2 assay (Fig. 17C, E). Neocortex and hippocampus cultures exhibited similar ATP levels, 
suggesting equivalent metabolic fitness (Fig. 17F). Piriform cortex exhibited higher ATP levels 
than neocortex at the highest concentrations of MG132 (Fig. 17D). Again, these regional 
differences may be attributable to the glia present in the cultures as they were not in agreement 
with the result of the MAP2 assay. Consistent with our previous findings with H2O2, entorhinal 
cortex cultures were more resistant to the oxidative toxin paraquat than neocortex cultures. Thus, 
the allocortex appears to possess antioxidant impressive defenses, although these are not 
sufficient to make it as resistant as neocortex to MG132. Taken together, these findings 
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demonstrate that neocortical neurons are more resistant to proteotoxicity than allocortical 
neurons, a phenomenon that is generalizable across multiple allocortical subregions.   
             
Figure 17: Regional differences in vulnerability to cellular stress. MAP2 content (A, C, E, G) and ATP levels (B, 
D, F, H) in neocortex cultures and cultures harvested from entorhinal, piriform, and hippocampal allocortex 48h 
after treatment with the proteasome inhibitor MG132 or the oxidative toxin paraquat. Fitted curves were 
extrapolated from non-linear regression analyses after conversion of the X-axis to a log scale. MAP2 and ATP levels 
at 0 µM MG132 were set to 100% (not shown in log scale graphs). For ease of presentation, concentrations of 
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MG132 are listed in micromolar units rather than in log units on the X-axis. Neocortical neurons were more resistant 
to proteotoxic stress from MG132 than neurons from three allocortical subregions according to the MAP2 assay, but 
less resistant to oxidative stress from paraquat. The ATP metabolic assay agreed with some, but not all of the MAP2 
In-Cell Westerns. Shown are the mean ± SEM of 3-4 independent experiments.  * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 
0.001, **** p ≤ 0.0001 neo- vs allocortex, Bonferroni post hoc correction following two-way ANOVA. Reprinted 
from Neurobiology of Aging, 36 (5), J. Posimo, J. Weilnau, A. Gleixner, M. Broeren, N. Weiland, J. Brodsky, P. 
Wipf, and R. Leak, “Heat shock protein defenses in the neocortex and allocortex of the telencephalon,” p. 1924-
1937. Copyright 2015 by Elsevier, reprinted with permission from Elsevier. 
 
Heat Shock Protein and Co-chaperone Expression in Neo- and Allocortex 
Heat shock proteins are molecular chaperones that can prevent the aggregation of 
unfolded/misfolded polypeptides by refolding them or directing irreparably damaged proteins to 
the proteasome for catalytic removal (Feder & Hofmann, 1999). Thus, heat shock proteins are 
important modulators of cell survival in neurodegenerative diseases. The molecular chaperone 
Hsp90 interacts with a number of co-chaperones as well as Hsp70 to prevent protein aggregation. 
Studies have shown that Hsp90 is consistently found in α-synuclein inclusions such as Lewy 
bodies and Lewy neurites and in tau inclusions (Uryu et al., 2006).  The co-chaperone CHIP is 
recruited to Hsp90 or Hsp70 complexes when protein refolding is inefficient, in order to promote 
client protein ubiquitylation and degradation through the proteasome (Labbadia & Morimoto, 
2015). CHIP has been shown to decrease α-synuclein aggregations in vitro and in vivo (Dimant 
et al., 2014). We found that levels of Hsp90 and the co-chaperone CHIP were not significantly 
different in neo- and allocortical cultures as a function of MG132 treatment, with the exception 
of a significant drop in neocortical levels of CHIP when comparing the data from 0.125 µM 
MG132 treatment with 0.25 µM MG132 treatment, forming a U-shaped concentration-response 
curve (Fig. 18A, B).  
The co-chaperones Hop and Hip mediate the association of Hsc70 and Hsp90, acting as 
folding cofactors and facilitating the maturation of client proteins (Taipale et al., 2010). There 
was a significant rise in the co-chaperones Hip and Hop in neocortical cultures in response to 
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0.125 µM MG132 (Fig. 18C, D). Additionally, neocortical cultures expressed significantly 
higher levels of Hip in response to 0.125 µM MG132 than allocortical cultures. Hsp70 levels 
rose significantly higher in allocortex than neocortex following MG132 treatment (Fig. 18E).  
Hsc70 is the constitutively expressed form of Hsp70 and guides misfolded proteins containing 
the C-terminal KFERQ motif to the lysosome for degradation (Arias & Cuervo, 2011). Hsc70 
levels are known to decline in the SNpc in Parkinson’s disease (Alvarez-Erviti et al., 2010; Chu, 
Dodiya, Aebischer, Olanow, & Kordower, 2009; Mandel et al., 2005). We found that Hsc70 
levels were significantly higher in allocortex than neocortex cultures in response to the highest 
concentration of MG132 (Fig. 18F).  
The small heat shock protein Hsp25 forms multimeric oligomers that trap misfolded 
proteins, preventing the formation of protein aggregations and providing a reservoir of client 
substrates for the Hsp70 machinery (Haslbeck et al., 2005). Hsp25 and HO1 levels were 
increased to greater levels in allocortical than neocortical cultures following MG132 treatment 
(Fig. 18G, H). Hsp40 acts as a co-chaperone of Hsp70, positively regulating its activity by 
stimulating ATPase activity (Kampinga & Craig, 2010). Hsp60 encapsulates proteins to prevent 
aggregation while refolding occurs (Kim et al., 2013). Low concentrations of MG132 elicited a 
rise in Hsp40 levels in neo- and allocortex cultures, whereas Hsp60 levels were unaffected (Fig. 
18I, J). The increased allocortical levels of Hsp70, Hsc70, HO1, and Hsp25 in response to 
MG132 demonstrate that allocortex mounts more robust stress responsive changes than 
neocortex.  
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Figure 18: Heat shock protein and co-chaperone expression in neo- and allocortical cultures. Levels of the heat 
shock proteins Hsp90, Hsp70, Hsc70, HO1, Hsp25, Hsp60, and Hsp40 (A, E, F, G, H, I, J) and the co-chaperones 
CHIP, Hip, and Hop (B, C, D) in neo- and allocortical (entorhinal) cultures 24h after treatment with MG132, as 
measured by infrared two-color Western blotting. Allocortex exhibited greater MG132-induced increases in Hsp70, 
Hsc70, HO1, and Hsp25, but neocortex exhibited greater stress-induced increases in Hip and Hop. Shown are the 
mean ± SEM of 6 independent experiments. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 vs neocortex, + p ≤ 0.05, ++ p ≤ 
0.01, +++ p ≤ 0.001 vs 0 µM MG132, ^ p ≤ 0.05, ^^ p ≤ 0.01 vs 0.125 µM MG132,  LSD post hoc following two-
way ANOVA. Reprinted from Neurobiology of Aging, 36 (5), J. Posimo, J. Weilnau, A. Gleixner, M. Broeren, N. 
Weiland, J. Brodsky, P. Wipf, and R. Leak, “Heat shock protein defenses in the neocortex and allocortex of the 
telencephalon,” p. 1924-1937. Copyright 2015 by Elsevier, reprinted with permission from Elsevier. 
 
Allocortex Relies More on Hsp70/Hsc70 than Neocortex Under Proteotoxic Conditions 
Next we used the Hsp70 and Hsc70 activity inhibitors VER155008 and MAL3-101 to 
determine the functional consequences of the robust increases in Hsp70 and Hsc70 levels with 
MG132 treatment.  According to both the MAP2 and ATP assays, VER155008 and MAL3-101 
exacerbated MG132 toxicity in neo- and allocortex (Fig. 19A-D). Furthermore, this exacerbation 
of toxicity was more pronounced in allocortex than neocortex according to the MAP2 assay (Fig. 
19A, C). In order to further assess the potential role of Hsp70 and Hsc70 induction, the 
Hsp70/Hsc70 activator 115-7c was applied. Treatment with various concentrations of 115-7c 
protected neocortical but not allocortical cultures from MG132 toxicity, even in experiments in 
which the proteasome inhibitor was especially toxic (Fig. 19E, F). We repeated the viability 
measurements after treatments with various concentrations of MG132 and the most protective 
concentration of 115-7c. In these latter experiments, only neocortical neurons were significantly 
protected by 115-7c against 1 and 2 µM MG132 (Fig. 19G). It is possible that 115-7c does not 
robustly protect allocortical cultures because Hsp70 molecules are already maximally engaged 
due to an overwhelming number of misfolded proteins. Thus, the effects of MG132, 
VER155008, and 115-7c on the K48-linked ubiquitinated protein pool were subsequently 
examined in order to test the hypothesis that allocortex possesses higher levels of misfolded 
proteins. As expected, allocortex expressed significantly higher levels of K48-linked 
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ubiquitinated proteins than neocortex when treated with 0.125 µM MG132 (Fig. 19H). However 
at 1 µM MG132, a concentration at which the MAP2 and ATP assays showed neo- and 
allocortex to be equally vulnerable, there was no significant difference in K48-linked 
ubiquitinated proteins (Fig. 19I). Further, neither VER155008 nor 115-7c had any effect on K48-
linked ubiquitination levels in neo- or allocortex, indicating that Hsp70 and Hsc70 activity may 
not modulate this measure.  
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Figure 19: Allocortical neurons rely more on Hsp70/Hsc70 than neocortical neurons under proteotoxic conditions. 
MAP2 and ATP levels in neo- and allocortical (entorhinal) cultures treated with MG132 and the Hsp70/Hsc70 
inhibitors VER155008 (A, B) or MAL3-101 (C, D), and the Hsp70 activity enhancer 115-7c for 48h (E-G). See text 
for details on MG132 concentrations in E & F. Loss of Hsp70/Hsc70 activity with VER155008 or MAL3-101 
synergistically exacerbated cell loss in response to MG132 according to the MAP2 assay, especially in allocortical 
neurons. Enhancement of Hsp70 activity with 115-7c protected neocortical neurons against proteotoxicity better 
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than allocortical neurons. (H, I) K48-linked ubiquitinated proteins in neo- and allocortical cultures treated 24h with 
MG132 and VER155008 or MG132 and 115-7c. Ubiquitinated protein levels were higher in allocortical cultures 
than neocortical cultures after treatment with low concentrations of MG132 (0.125 µM). Hsp70 activity 
manipulation with VER155008 and 115-7c exerted no effects on ubiquitinated proteins. Shown are the mean ± SEM 
of 3-7 independent experiments. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 vs neocortex, + p ≤ 0.05, ++ p ≤ 0.01, +++ p 
≤ 0.001, ++++ p ≤ 0.0001 vs 0 µM MG132, ~ p ≤ 0.05, ~~ p ≤ 0.01, ~~~ p ≤ 0.001, ~~~~ p ≤ 0.0001 vs 0 µM 
VER155008, MAL3-101, or 115-7c,  Bonferroni post hoc correction following three-way ANOVA for MAP2 and 
ATP assays or LSD post hoc correction following three-way ANOVA for immunoblotting data. Reprinted from 
Neurobiology of Aging, 36 (5), J. Posimo, J. Weilnau, A. Gleixner, M. Broeren, N. Weiland, J. Brodsky, P. Wipf, 
and R. Leak, “Heat shock protein defenses in the neocortex and allocortex of the telencephalon,” p. 1924-1937. 
Copyright 2015 by Elsevier, reprinted with permission from Elsevier. 
 
 Allocortex Relies more on HO1 to Defend against Proteotoxicity than Neocortex 
In our comprehensive examination of heat shock proteins, HO1 levels were found to be 
higher in allocortical cultures than neocortical cultures following MG132 treatment (Fig. 8G). 
This suggests that allocortex may rely more on HO1 than neocortex to defend against 
proteotoxicity, similar to the Hsp70/Hsc70 data. The HO1 inhibitor SnPP was applied to directly 
test this hypothesis. As expected, MG132 toxicity was synergistically potentiated in allocortex 
more than neocortex (Fig. 20A). However, allocortex had higher ATP levels after MG132 
treatment than neocortex in the presence of SnPP, suggesting that allocortex was either less 
metabolically vulnerable to HO1 activity loss or that it increased ATP output in response to 
greater stress (Fig. 20B).  
  
Figure 20: Allocortical neurons rely on HO1 more than neocortical neurons under proteotoxic conditions. (A, B) 
MAP2 and ATP levels were assessed in neo- and allocortical cultures 48h after treatment with the HO1 activity 
inhibitor tin protoporphyrin (SnPP) and MG132. Loss of HO1 activity synergistically exacerbated MG132 toxicity 
according to the MAP2 assay, especially in allocortical neurons. However, loss of ATP in response to VER155008 
and MG132 co-treatment was not as severe in allocortical cultures as in neocortical cultures. Shown are the mean ± 
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SEM of 3-4 independent experiments. ** p ≤ 0.01, **** p ≤ 0.0001 vs neocortex, + p ≤ 0.05, ++ p ≤ 0.01, ++++ p ≤ 
0.0001 vs 0 µM MG132, ~~ p ≤ 0.01, ~~~~ p ≤ 0.0001 vs 0 µM SnPP,  Bonferroni post hoc correction following 
three-way ANOVA. Reprinted from Neurobiology of Aging, 36 (5), J. Posimo, J. Weilnau, A. Gleixner, M. Broeren, 
N. Weiland, J. Brodsky, P. Wipf, and R. Leak, “Heat shock protein defenses in the neocortex and allocortex of the 
telencephalon,” p. 1924-1937. Copyright 2015 by Elsevier, reprinted with permission from Elsevier. 
 
Neo- and Allocortical Astrocytes Do Not Differ in their Reliance on Hsp/Hsc70 Defenses 
As mentioned previously, our neo- and allocortical cultures contain a small percentage of 
glia, including GFAP+ astrocytes. The number of GFAP+ cells was similar in neo- and allocortex, 
although GFAP staining was more intense in allocortex (9.5% GFAP+ cells in neocortex; 13.2% 
GFAP+ cells in allocortex) (Fig. 21A). Consequently, there were higher levels of GFAP in 
allocortex than neocortex by Western blot analyses (Fig. 21B). These findings raised the 
possibility that distinct astrocytic responses in neocortical and allocortical cultures may 
contribute to the differential effects of MG132 and the Hsp70/Hsc70 modulators. To examine 
this question, neocortical and allocortical astrocytes were cultured in parallel and treated with 
VER155008 and MG132 in collaboration with Justin Weilnau. Neocortex-derived astrocyte 
cultures were found to be 92% GFAP+ and allocortex-derived astrocyte cultures were 95% 
GFAP+. Blinded counts of Hoechst+ nuclei revealed only slight exacerbation of MG132 toxicity 
with VER155008 in neocortical astrocytes and no significant differences between neo- and 
allocortical astrocytes (Fig. 21C, H). In addition, DRAQ5 nuclear staining revealed that MG132 
toxicity was only slightly exacerbated by VER155008 in both neo- and allocortical astrocyte 
cultures (Fig. 21D, E). There was no exacerbation of MG132 toxicity with VER155008 as 
assessed by the ATP assay, even when ATP levels were expressed as a function of cell numbers, 
a measurement of ATP output per cell (Fig. 21F, G). However, ATP output per cell rose with 
MG132 in allocortical astrocytes treated with VER155008, a sign of greater metabolic stress 
(Fig. 21G). Nevertheless, neo- and allocortical astrocytes exhibited no significant differences by 
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any of the three assays (Hoechst+ cell numbers, DRAQ5 levels, and ATP levels). In sum, these 
findings support the view that the differences in reliance on Hsp70 defenses in neo- and 
allocortex is neuronal and not astrocytic in origin.   
 
Figure 21: Neo- and allocortical astrocytes do not differ in their reliance on Hsp70/Hsc70 defenses.  (A) Neo- and 
allocortical (entorhinal) neuronal cultures were stained for MAP2, GFAP, and Hoechst. Some GFAP+ astrocytes 
were visible in both cultures. Omission of primary antibodies led to loss of fluorescent signal. (B) Western blots for 
GFAP verify the presence of this protein in cultures from both brain regions and reveal that GFAP protein levels are 
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higher in allocortex cultures. Shown are the mean ± SEM of 6 independent experiments. ** p ≤ 0.01 vs neocortex, 
two-tailed Student’s t-test. (C-H) Astrocyte cultures harvested from neo- and allocortex were treated with MG132 
and the Hsp70/Hsc70 inhibitor VER155008 for 48h and the number of Hoechst+ cells, DRAQ5 nuclear staining, and 
ATP levels were assessed. ATP levels were also expressed as a function of Hoechst+ cells in panel G. 
Representative DRAQ5 and Hoechst images from the data in panels C and D are shown (E, H). Unlike in neurons, 
there was no robust exacerbation of MG132 toxicity in neo- or allocortical astrocytes after loss of Hsp70/Hsc70 
activity, even at higher concentrations of VER155008. Shown are the mean ± SEM of 3 independent experiments. + 
p ≤ 0.05, ++ p ≤ 0.01 vs 0 µM MG132, Bonferroni post hoc correction following three-way ANOVA. Reprinted 
from Neurobiology of Aging, 36 (5), J. Posimo, J. Weilnau, A. Gleixner, M. Broeren, N. Weiland, J. Brodsky, P. 
Wipf, and R. Leak, “Heat shock protein defenses in the neocortex and allocortex of the telencephalon,” p. 1924-
1937. Copyright 2015 by Elsevier, reprinted with permission from Elsevier. 
 
Hsp70 Inhibition Does Not Exacerbate Paraquat Toxicity in Neo- and Allocortex 
 Hsp70 defenses are essential to combat toxicity associated with protein misfolding stress. 
Our previous work has shown that Hsp70 is less effective against oxidative toxicity (Crum et al., 
2015). In order to verify this in the current model, we treated neo- and allocortical cultures with 
the oxidative toxin paraquat and the Hsp70/Hsc70 activity inhibitors VER155008 and MAL3-
101. No robust effect was observed when these inhibitors were applied in conjunction with 
paraquat in either neo- or allocortical cultures, supporting our previous work that Hsp70 defenses 
are not essential for protection against oxidative toxins (Fig. 22A-D). Finally, heat shock protein 
levels were examined in neo- and allocortex cultures after treatment with paraquat. Paraquat 
treatment did not elicit any significant changes in Hsp90, Hsp60, Hsp40, or Hsc70 levels in neo- 
and allocortex cultures (Fig. 22E-H). Furthermore, Hsp70 levels were undetectable in neo- and 
allocortical cultures treated with paraquat, suggesting that Hsp70 is not even upregulated in 
response to oxidative stress. On the other hand, HO1 levels rose significantly higher in 
allocortical cultures than neocortical cultures after paraquat treatment (Fig. 22I). Furthermore, 
allocortex expressed significantly higher levels of Hsp25 than neocortex with and without 
paraquat treatment (Fig. 22J). These results support the view that allocortex responds to 
oxidative stress with a greater increase in Hsp25 and HO1 than neocortex but that Hsp70 is not 
engaged in response to paraquat exposure. These finding are consistent with previous studies in 
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which HO1 and Hsp25 are induced by free-radical injury (Maines & Panahian, 2001; Merendino 
et al., 2002). 
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Figure 22: Paraquat toxicity in neo- and allocortical neurons is not exacerbated by Hsp70/Hsc70 inhibition. MAP2 
and ATP levels in neo- and allocortical (entorhinal) cultures 48h after treatment with paraquat or vehicle in the 
absence or presence of the Hsp70/Hsc70 inhibitors VER155008 (A, B) or MAL3-101 (C, D). Paraquat-induced cell 
loss was not robustly exacerbated by inhibition of Hsp70/Hsc70 activity in either neo- or allocortical neurons 
according to the MAP2 and ATP assays. Expression of heat shock proteins Hsp90, Hsp60, Hsp40, Hsc70, HO1, and 
Hsp25 in neo- and allocortical cultures treated with paraquat (E-J). Of all the proteins shown, paraquat only 
increased levels of the antioxidant defense protein HO1 in allocortical cultures. Allocortical cultures had higher 
levels of HO1 and Hsp25 than neocortical cultures. Shown are the mean ± SEM of 3-6 independent experiments. * p 
≤ 0.05, *** p ≤ 0.001 vs neocortex, + p ≤ 0.05, +++ p ≤ 0.001 vs 0 µM paraquat, ~ p ≤ 0.05, ~~ p ≤ 0.01 vs 0 µM 
VER155008 or MAL3-101, ^^^ p ≤ 0.001 vs 3.125 µM paraquat, Bonferroni post hoc correction following three-
way ANOVA for MAP2 and ATP data or LSD post hoc correction following two-way ANOVA for immunoblotting 
data. Reprinted from Neurobiology of Aging, 36 (5), J. Posimo, J. Weilnau, A. Gleixner, M. Broeren, N. Weiland, J. 
Brodsky, P. Wipf, and R. Leak, “Heat shock protein defenses in the neocortex and allocortex of the telencephalon,” 
p. 1924-1937. Copyright 2015 by Elsevier, reprinted with permission from Elsevier. 
 
Discussion 
The goal of Specific Aim 2 was to assess the role of heat shock proteins in neocortical 
and entorhinal allocortical neurons as a defense against proteotoxic stress. In support of our 
hypothesis, we found that neocortex is more resistant to loss of protein homeostasis.  Given the 
stress-inducible nature of heat shock proteins, the results of this Specific Aim suggest that 
allocortex cultures are under greater levels of proteotoxic stress, because Hsp70 and Hsc70 levels 
were higher in allocortical cultures after treatment with low concentrations of MG132. This view 
is strongly supported by the viability measurements, because allocortical neurons exhibited a 
greater propensity to die following toxic proteasome inhibition, especially when Hsp70/Hsc70 
activity was simultaneously inhibited. Proteotoxic stress is defined as an increased burden of 
misfolded proteins and subsequent loss of protein homeostasis, and is reflected in the K-48 
ubiquitinated protein pool (Sadowski & Sarcevic, 2010). As expected, allocortical cultures 
expressed higher levels of K-48 ubiquitinated proteins than neocortical cultures after treatment 
with MG132. Furthermore, the Hsp70 activator 115-7c protected neocortical but not allocortical 
cultures against MG132-induced proteotoxicity. This lack of significant protection is also likely 
to reflect greater proteotoxicity in allocortical than neocortical cultures. For example, allocortical 
Hsp70 molecules may already be maximally engaged due to the higher burden of misfolded 
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proteins in neurons from allocortex. Perhaps as a result, Hsp70 activity cannot be further 
stimulated to elicit neuroprotection and more protein would need to be expressed to have a 
significant effect upon protein misfolding. Thus, we hypothesize that allocortical cultures mount 
a greater heat shock protein response due to greater levels of proteotoxic stress, but that this 
response seems insufficient to render it as resistant as neocortex. In conclusion, our studies 
support the view that brain region specific Hsp70- and Hsc70-based therapies or heat shock gene 
induction will slow or prevent neuronal cell death in proteinopathic conditions such as 
Parkinson’s or Alzheimer’s disease. 
 As many studies have reported highly protective effects of HO1, the effect of HO-1 
inhibition was also assessed in our in vitro model in order to reveal potential neo/allocortical 
differences (Calabrese et al., 2009). The HO1 inhibition and Western blotting experiments reveal 
that allocortex cells rely more on HO1 for protection against proteotoxicity than neocortex cells, 
similar to the Hsp70 data. In addition, Hsp25 levels were also elevated to higher levels in 
allocortex than neocortex with MG132 treatment. Taking both our Hsp70/Hsc70 and HO1 
findings into consideration, we speculate that allocortex also relies more heavily on Hsp25 for 
protection than neocortex. Further studies with Hsp25 inhibitors are needed to test this 
hypothesis directly.  
 The reason underlying the greater vulnerability of allocortex to proteasomal stress is still 
unclear, as allocortical cells did not exhibit overall lower levels of defensive proteins.  However, 
allocortical neurons are known to exhibit less myelination and greater accumulation of 
lipofuscin, a byproduct of failed lysosomal degradation, and may therefore be subject to greater 
levels of oxidative and proteotoxic stress in humans (H. Braak, Rüb, et al., 2003). It is possible 
that allocortex evolved to express higher levels of antioxidant and chaperone proteins due to a 
 91 
greater risk of proteotoxicity with aging. Despite these attempts, the additional defenses are 
insufficient to make allocortex quite as resilient to loss of protein homeostasis as neocortex. It is 
possible that the relative resilience of the neocortex observed in the present study is related to 
higher expression of the co-chaperones Hip and Hop after proteotoxic stress exposure. We 
previously showed that neocortex also expresses higher levels of the ferroxidase ceruloplasmin 
and the antioxidant glutathione, both of which were not stress-responsive in our model. Further, 
neocortex appeared to rely on autophagy to combat proteotoxicity whereas allocortex did not 
(Posimo, Titler, Choi, Unnithan, & Leak, 2013). In addition to these explanations, the differential 
vulnerability of the neocortex and allocortex to human diseases may reflect their vastly different 
efferent and afferent connectomes.  
 Astrocytes are known to develop inclusions in a similar staging pattern as the 
intraneuronal pathology (H. Braak, Sastre, & Del Tredici, 2007). Furthermore, evidence suggests 
that astrocytes are subjected to proteotoxic stress in neurodegenerative conditions. For example, 
astrocytes can remove α-synuclein from the extracellular space and upregulate heat shock 
proteins (H. Braak et al., 2007; Dabir, Trojanowski, Richter-Landsberg, Lee, & Forman, 2004; 
Durrenberger et al., 2009; Lee et al., 2010; Renkawek, Stege, & Bosman, 1999; Seidel et al., 
2012). In the present study, no significant differences between neo- and allocortical astrocytes 
were observed. These findings support the view that the differences observed in our mixed 
cultures are largely neuronal in origin. 
 The results of our MAP2 and ATP assays are not always in agreement. Both assays have 
been validated in multiple publications and shown to measure distinct aspects of cellular fitness 
(Posimo et al., 2013; Posimo et al., 2014; Unnithan, Choi, Titler, Posimo, & Leak, 2012). As 
mentioned above, ATP levels are often upregulated in stressed cells, suggesting that this assay 
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cannot be used as an approximation of cell numbers as claimed by the manufacturer. 
Furthermore, the ATP measurements do not distinguish between neurons and glia. Thus, higher 
ATP levels may not represent higher cell numbers but may suggest greater metabolic stress, in 
either neurons or glia or both. Further studies to determine ATP output as a function of cell 
numbers in purely neuronal models would help to address this limitation.  
 As discussed previously, limitations of this study include the possible selection of cells 
predisposed to survive the culturing process. On the other hand, if resistant neo- and allocortical 
cells were indeed selected differently during the culturing protocol, such a difference would not 
explain why both survived equally well under basal conditions in Neurobasal-A media. 
Differential survival of the culturing protocol would also not explain why neocortical cells were 
more resistant to proteasome inhibitors but less resistant to oxidative toxins. Another limitation 
of this study may be that neo- and allocortex are at different developmental stages when 
harvested on postnatal day 1 or 2. For example, allocortex may develop more rapidly than 
neocortex during embryonic life and thus may experience more mechanical stress due to greater 
shearing of axonal projections and dendritic processes upon trituration and dissociation 
(Kostovic, 1990; Kostovic, Petanjek, & Judas, 1993; Prayer, 2011). However, this would also not 
explain why vulnerabilities to proteasome inhibitors and oxidative toxins are reversed. Finally, 
although varying amounts of non-neuronal elements such as glia may contribute to differential 
responses to cellular stress, our astrocyte culture data do not suggest that this is a serious 
confound.  
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Chapter 3  
Specific Aim 3: Characterize the age-related changes in antioxidant and heat shock protein 
profiles of the neo- and allocortex in vivo. Based on our in vitro findings, we hypothesize that 
levels of stress sensitive proteins will increase more in allocortex than neocortex with age.  
Rationale 
 Aging is a natural model of proteotoxicity and the major risk factor for neurodegenerative 
diseases (Dasuri et al., 2009; Keller, Gee, & Ding, 2002; Keller, Hanni, & Markesbery, 2000). 
Additionally, aging has been associated with increased oxidative damage since the 1950s 
(Harman, 1956). Thus, we examined the impact of aging on defensive proteins such as 
glutathione, heat shock proteins, and proteins related to the proteasome in neo- and allocortex in 
vivo.  
Results 
Neocortex and Allocortex Respond Differently to Aging In Vivo 
 As discussed in Specific Aim 1b, glutathione levels were found to be significantly higher 
in neocortex than allocortex in vitro (Fig. 23A). Therefore, we wanted to establish whether 
glutathione levels exhibited similar patterns in vivo.  Glutathione levels were measured in rat 
brain tissue as a function of age (Fig. 23A). Surprisingly, no significant differences were found 
between neo- and allocortical levels of glutathione at any age. However, allocortical glutathione 
levels were significantly higher at 19-22 months than at 2-4 months of age (Fig. 23A).  
Moreover, a linear regression analysis revealed a significant correlation between age and 
glutathione levels in allocortex but not in neocortex (p = 0.0136, R2 = 0.9014). This age-related 
rise in allocortical glutathione levels may be a compensatory mechanism against a parallel 
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increase in age-related cellular stress. Alternatively, aged allocortex may survive oxidative 
insults better than aged neocortex, as shown for postnatal cultures in vitro. 
Next we measured levels of ubiquitin-conjugated proteins and PA28 to assess age-related 
proteasomal stress. Ubiquitin-conjugated protein levels were not significantly different between 
neo- and allocortex and did not rise with aging (data not shown). Neocortical PA28 levels were 
significantly higher in 19-22 month than 2-4 month old animals. However, allocortical PA28 
levels were significantly higher at 16-19 months than 2-4 months of age. Furthermore, PA28 
levels were higher in allocortex than neocortex at every age (Fig. 23B, C). At 19-22 months, neo- 
and allocortical PA28 levels were no longer significantly different, supporting the view that 
neocortex and allocortex may display equivalent levels of proteasomal stress toward the end of 
life.  
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Figure 23. Impact of natural aging on neocortex and allocortex in vivo. A: Glutathione levels in whole tissue lysates 
of rat neo- and allocortex as a function of age. Allocortical glutathione levels were similar to those in neocortex but 
rose in an age-dependent manner and were significantly higher at 19-22 months of age relative to the youngest 
group (2-4 months). Neocortical glutathione did not change significantly as a function of age. B-C: Western 
immunoblotting for PA28 levels as a function of age and brain region. PA28 levels rose in neocortex at 19-22 
months and in allocortex at 16-19 months relative to the youngest age group. Allocortical PA28 levels were 
significantly higher than in neocortex at 16-19 months of age. Data are expressed as mean and standard error of the 
mean from 4-5 rats per group. For all panels, ** p ≤ 0.01, allocortex versus neocortex; + p ≤ 0.05, +++ p ≤ 0.001 
versus levels in the 2-4 month old group; Bonferroni post hoc correction following two-way ANOVA. Reprinted 
from “Neocortex and Allocortex Respond Differentially to Cellular Stress In Vitro and In Vivo,” by J. Posimo, A. 
Titler, H. Choi, A. Unnithan, and R. Leak 2013, PLoS ONE, 8(3): e58596. doi:10.1371/journal.pone.0058596. 
Copyright 2013 by Posimo et al.  Reprinted with permission. 
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Heat Shock Protein Expression in Neo- and Allocortex as a Function of Age In Vivo 
 In addition to glutathione measurements, we examined the impact of aging on heat shock 
protein expression in neocortical and allocortical tissue from female rats. Hsp90 and CHIP levels 
were significantly higher in neo- than allocortex in the 19-22 month old group (Fig. 24A, B). 
However, CHIP levels were significantly higher in allocortex than neocortex in the youngest 
animals. In addition, CHIP levels were significantly higher at all ages in neocortex and at 16-19 
months in allocortex compared to levels in the 2-4 month old animals.  CHIP levels in allocortex 
were decreased at 19-22 months compared to the youngest animals. Neocortical Hsp90 levels 
were raised in the 16-19 and 19-22 month old animals compared to the 2-4 month old group. The 
lower levels of Hsp90 and CHIP in aged allocortex compared to aged neocortex may indicate a 
collapse of chaperone defenses in this brain region. 
 Hip levels are significantly higher in allocortex than neocortex at 2-4 months (Fig. 24C). 
Furthermore, Hip levels were significantly increased in neocortex in the 4-6 month group 
compared to the youngest animals. Hsp70 levels peaked in neo- and allocortex at 8-9 months but 
returned to lower levels thereafter (Fig. 24F). HO1 levels were higher in allocortex than 
neocortex at 2-4 and 8-9 months of age (Fig. 24G). Hsp25 levels in allocortex were higher in the 
19-22 month old group compared to the youngest animals (Fig. 24H). No significant changes as 
a function of age or brain region of origin were observed for Hop, Hsc70, Hsp60, or Hsp40 (Fig. 
24D-E, I-J). It is noteworthy that HO1 and Hsp25 levels were higher in allocortex than neocortex 
at some ages, consistent with the in vitro data showing higher stress-induced changes in the these 
proteins following MG132 treatment. 
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Figure 24: Heat shock proteins and co-chaperones in neo- and allocortex as a function of age in vivo. Female rats 
were sacrificed at 2-3.9, 4-6, 8-9, 16-18.9, and 19-22 months of age. Heat shock proteins Hsp90, Hsc70, Hsp70, 
HO1, Hsp25, Hsp60, and Hsp40 (A, E, F, G, H, I, J) and co-chaperones CHIP, Hip, and Hop (B, C, D) were 
measured in sensorimotor neocortex and entorhinal allocortex by infrared immunoblotting. Allocortical tissue 
exhibited higher levels of HO1 at multiple ages and higher levels of Hip at the youngest age. Age-related changes 
(usually increases) in Hsp90, CHIP, Hip, Hsp25 and Hsp70 were also apparent. Allocortical tissue exhibited lower 
levels of Hsp90 and CHIP than neocortical tissue in the oldest group, but allocortex and neocortex expressed 
equivalent levels of Hsp70 at all ages. n= 3-6 animals per group. * p ≤ 0.05, *** p ≤ 0.001 vs neocortex, + p ≤ 0.05, 
++ p ≤ 0.01, +++ p ≤ 0.001 vs 2-4 mo., # p ≤ 0.05 vs 4-6 mo., ^ p ≤ 0.05, ^^ p ≤ 0.01 vs 8-9 mo.,  ~ p ≤ 0.05, ~~~ p 
≤ 0.001 vs 19-22 mo., LSD post hoc correction following two-way ANOVA. Reprinted from Neurobiology of 
Aging, 36 (5), J. Posimo, J. Weilnau, A. Gleixner, M. Broeren, N. Weiland, J. Brodsky, P. Wipf, and R. Leak, “Heat 
shock protein defenses in the neocortex and allocortex of the telencephalon,” p. 1924-1937. Copyright 2015 by 
Elsevier, reprinted with permission from Elsevier. 
 
Discussion 
            This study compares regional variations in antioxidant, proteasomal, and heat shock 
protein defenses in the sensorimotor neocortex and entorhinal allocortex in vivo, and determines 
the impact of aging on these topographical patterns. Our hypothesis that levels of stress sensitive 
molecules would be raised to greater levels in allocortex than neocortex with aging was 
supported by some (eg. Hsp25, HO1), but not all molecules.  
Glutathione levels were significantly different between neo- and allocortex in our in vitro 
model in either the absence or presence of MG132. Thus, we sought to assess glutathione levels 
in these regions as a function of age in vivo. However, we found that glutathione levels were 
similar between neo- and allocortex across all ages. This discrepancy between our in vitro and in 
vivo results may have arisen because our primary cultures are mainly neuronal, whereas the 
cortical tissue lysates contain large numbers of glia, particularly astrocytes. Astrocytes are the 
major source of glutathione in the brain and differences between neo- and allocortical neurons 
may have been masked by their abundant presence in the lysates. Furthermore, the postnatal time 
of harvest of neo- and allocortex may also help explain the discrepancy between the two sets of 
data. For example, neocortical cells might have higher levels of glutathione than allocortical cells 
neonatally but this difference might be lost upon further brain development into adulthood. 
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Future flow cytometry studies that distinguish neurons from astrocytes would be valuable to test 
the hypothesis that neocortical neurons have higher levels of glutathione than allocortical 
neurons in vivo. The rise in allocortical glutathione levels with age may be attributed to 
increasing levels of cellular stress as levels were highest in the oldest group and correlated 
robustly with advancing age. 
Ubiquitin-conjugated protein levels were similar in neo- and allocortex in vivo and did 
not rise with aging. Nonetheless, other studies have shown that proteasome activity is decreased 
in the cortex with aging (Dasuri et al., 2009; Keller et al., 2002; Keller et al., 2000). Age-related 
proteasomal stress in neo- and allocortex was supported by increases in PA28 expression. 
Allocortex expressed higher levels of PA28 than neocortex in 16-19 month old animals, 
suggesting that allocortex may be under greater levels of proteasome-related stress in vivo, 
consistent with the in vitro findings. However, PA28 levels in the oldest group were similar in 
neo- and allocortex, suggesting that neocortex experiences some proteasome-related stress later 
in life.  
 When examining heat shock protein levels in vivo, many differences from our in vitro 
data (Chapter 2, Figure 18) were observed. Once again, the discrepancies may have arisen 
because of greater number of astrocytes in vivo or the postnatal time of harvest for the in vitro 
cultures. Additionally, the insults applied to these samples are quite distinct, as proteasome 
inhibition is certainly not the same as natural aging. Levels of Hsp70 were similar between neo- 
and allocortex in vivo whereas MG132-stressed allocortical neurons exhibited higher expression 
of this heat shock protein in vitro. In addition, allocortex expressed higher levels of the co-
chaperone Hip in the youngest animals, whereas MG132-treated neocortex expressed higher 
levels in vitro. In contrast, the pattern of HO1 expression in neo/allocortical cultures was in 
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agreement with the pattern of expression in tissue. Thus, HO1 levels were higher in allocortex at 
several ages in vivo and following paraquat and MG132 treatment in vitro. Hsp90 and CHIP 
levels were higher in neocortex than allocortex in the oldest aged animals, a finding that may 
warrant further examination in age-related diseases. Finally, Hsp25 levels were increased in 
allocortex both with age in vivo and with MG132 treatment in vitro. This finding is in agreement 
with previous work showing higher expression of this protein in the cortex, striatum, substantia 
nigra, and the olfactory bulb of aged animals relative to younger controls (Crum et al., 2015; 
Dickey et al., 2009; Gleixner et al., 2014; Gupte et al., 2010; Schultz et al., 2001). 
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Conclusion                                  
 In conclusion, we have discovered a number of differences in neo- and allocortical cells, 
strongly supporting the view that brain region and selective vulnerabilities must be taken into 
account when modeling diseases and designing new therapies. Previous studies are in general 
agreement that topographic differences in vulnerability are common in the central nervous 
system. For example, Mattson and colleagues demonstrated that the CA1 and CA3 subregions of 
the hippocampus are less resistant than other hippocampal areas (Mattson, Guthrie, & Kater, 
1989). In the substantia nigra, caudal and ventrolateral dopaminergic neurons are more 
vulnerable than more rostral, dorsomedial dopaminergic neurons and neurons in the adjacent 
ventral tegmental area (H. Braak, Del Tredici, Rüb, et al., 2003; Damier et al., 1999). 
Furthermore, dopaminergic neurons in the retina do not degenerate in Parkinson’s disease and 
are more resistant to parkinsonian neurotoxins than dopaminergic neurons in the ventral 
mesencephalon (Nagel, Bahr, & Dietz, 2009). Our study now adds to this body of literature, as 
we are the first to demonstrate that allocortical neurons are more vulnerable to proteotoxic but 
not oxidative stress than neocortical neurons. These vulnerability differences are likely to be 
superimposed upon neuroanatomical connectivity differences to determine whether or not a 
given neuron develops protein inclusions in Parkinson’s disease. 
Multiple independent and unbiased viability assays helped us reach the abovementioned 
conclusions. An ATP assay and two infrared viability assays, nuclear staining with DRAQ5 and 
the In-Cell Western assay for the neuronal marker MAP2, were used in parallel to assess the 
functional and structural integrity of the cells in culture. Our ATP and infrared assays were linear 
and correlated with plating density, though not all assays were equally sensitive. Nevertheless, 
each assay was well in proportion to cell number at or below our chosen plating density of 
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100,000 cells per well. These viability assays were used as an alternative to the more laborious 
manual nuclear cell counts, which suffer from a number of disadvantages. On the other hand, all 
assays suffer from caveats and rely on assumptions that are not always met, as discussed 
previously in Specific Aim 1a. Our reliance on multiple assays helps mitigate the impact of the 
caveats of each individual assay. Furthermore, a more comprehensive view of cellular fitness can 
be achieved by using multiple assays. 
Using these assays in our in vitro model, allocortical neurons were found to be more 
resistant to H2O2 toxicity than neocortical neurons. This striking difference warrants further 
investigation as it suggests that allocortex has evolved impressive defenses against oxidative 
stress. However, neocortex was more resistant to proteasome inhibition than allocortex despite 
expressing lower levels of heat shock proteins, proteasomal subunits, and catalase. Consistent 
with the proteasome inhibitor data, neocortex did not form inclusions as readily as entorhinal 
cortex after treatment with α-synuclein fibrils. This suggests that entorhinal cortex is more 
vulnerable to proteotoxicity than neocortex, in agreement with postmortem studies of inclusion 
topography. Thus we have gathered support for the view that brain region of origin is a major 
determinant of inclusion formation, even in structures that are typically treated as a single unit in 
in vitro studies, such as the cerebral cortex.  
In our hands, α-synuclein fibrils were not able to elicit cell loss in vitro as previously 
reported. This may be due to differences in treatment protocol and sonicators, as discussed in 
Specific Aim 1c.  The hippocampus was the most susceptible to inclusion formation while 
olfactory bulb and neocortex were the least susceptible. These findings may be explained by our 
Western blotting data showing that basal levels of endogenous α-synuclein were highest in 
hippocampus. A recent study revealed that hippocampus has higher levels of α-synuclein 
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immunoreactivity compared to entorhinal cortex, neocortex, and specific regions of the olfactory 
bulb in the mouse brain, entirely consistent with our findings (Taguchi, Watanabe, Tsujimura, & 
Tanaka, 2015). These results suggest that abundant levels of α-synuclein may increase 
susceptibility to inclusion formation, as this protein is the major component of Lewy bodies. Our 
findings are also in agreement with work on α-synuclein knockout mice showing that 
endogenous α-synuclein expression is essential for the formation and spread of inclusions after 
injection of α-synuclein fibrils into the brain (Luk, Kehm, Carroll, et al., 2012). 
Allocortical neurons were significantly more vulnerable to loss of Hsp70/Hsc70 activity 
and less able to recover from MG132 toxicity upon enhancement of Hsp70 activity. Thus, 
allocortex may have been all the more vulnerable to proteotoxicity had it not raised heat shock 
protein defenses so robustly. Our findings indicate that pharmacotherapies or gene therapies 
boosting Hsp70 activity would be more protective in neocortex than allocortex. The chaperone 
system in allocortex may already be maximally engaged in response to protein misfolding stress, 
suggesting that therapies targeted to this region may need to involve other molecules besides 
Hsp70, such as glutathione, or induce the expression of greater numbers of Hsp70 molecules. 
Glutathione and ceruloplasmin were not found to be robustly stress-sensitive in our 
model and were basally higher in neocortex than allocortex in vitro.  Moreover, inhibition of 
glutathione synthesis rendered neo- and allocortex all the more vulnerable to proteasome 
inhibition. Consistent with these observations, enhancing glutathione synthesis with N-acetyl 
cysteine protected allocortex from MG132 toxicity. These findings support the view that high 
glutathione expression may be partially responsible for neocortical resistance to proteotoxic 
stress. In addition, inhibition of autophagy heightened neocortical vulnerability to proteotoxicity 
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but had no effect on MG132 toxicity in allocortex. Thus, neocortex (but not allocortex) may be 
relying on autophagic defenses to battle MG132-induced proteotoxicity.  
Limitations of our studies have been discussed throughout this document and will only be 
briefly mentioned here. For example, very young, postnatal day 1-2 rat neurons were used to 
model an age-related neurodegenerative disorder. It is possible that older neurons would respond 
differently, perhaps even showing greater intrinsic vulnerability differences than young 
neocortex and allocortex. For this reason, we also examined neo- and allocortical tissue as a 
function of age and found that CHIP and Hsp90 expression is lower in allocortex than neocortex 
in the oldest animals. We also recognize that neurons in vitro often respond differently than 
neurons in vivo. Many neuroanatomical circuits are disrupted in in vitro studies and the process 
of dissociation and adherence to plastic dishes may change protein expression and impact 
vulnerability patterns. Nevertheless, numerous investigators have used embryonic or postnatal 
cells as in vitro models of Parkinson’s and Alzheimer’s disease (Volpicelli-Daley et al., 2014a; 
Volpicelli-Daley et al., 2011a; Yao et al., 2009; Zhang et al., 2011).  
Another limitation of our studies is the reliance on pharmacological inhibitors, all of 
which surely exert off-target effects. For example, MG132 is also known to inhibit cathepsins 
and calpains, lysosomal and non-lysosomal proteases, in addition to the proteasome (Kisselev & 
Goldberg, 2001). These off-target effects would nevertheless all lead to further proteotoxicity, 
suggesting that the responses that we observe after treatment with MG132 can indeed be 
attributed to loss of protein homeostasis. Furthermore, there are decreases in both proteasomal 
and lysosomal functions in Parkinson’s disease (Cook, Stetler, & Petrucelli, 2012). Wherever 
possible, we attempted to use multiple inhibitors to decrease the impact of off-target effects on 
our interpretations. For example, neocortical neurons were more resistant to proteotoxicity than 
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allocortical neurons following exposure to three separate proteasome inhibitors (MG132, PSI, 
ALLN), a finding that was confirmed with α-synuclein fibril treatments. Furthermore, two 
Hsp70/Hsc70 activity inhibitors, VER155008 and MAL3-101, with unique mechanisms of action 
were applied to our in vitro model. 
 In conclusion, neocortex and allocortex respond differently when treated with toxins in 
vitro and to aging in vivo. The differential response of these regions to proteasome inhibition and 
α-synuclein fibril treatment parallels the clinical findings that human allocortex is more 
vulnerable to intracellular inclusions than neocortex in Alzheimer’s and Parkinson’s disease. 
This enhanced vulnerability to proteotoxicity may result in greater accrual of aggregated proteins 
in allocortical regions as a function of age and disease stage. Nevertheless, our findings indicate 
that allocortical neurons have impressive defenses against oxidative toxicity and exhibit multiple 
compensatory responses to proteotoxicity. Such allocortical defenses may help explain the slow 
and delayed nature of degeneration in Parkinson’s and Alzheimer’s disease. Enhancing such 
natural defenses in more vulnerable regions, including, but not limited to the allocortex, may 
further slow or perhaps even halt the progression of these disorders. 
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